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Ι Abbreviations 
 
5´ UTR  5´untranslated region 
3´ UTR  3´untranslated region 
µl   Microliter 
µg    Microgramm 
Amp    Ampicillin 
AA   Arachidonic acid 
Ago   Argonaute protein 
AP1   Activator protein 1 
AS    Alternative splicing 
ATCC    American Type Culture Collection 
ATP    Adenosintriphosphate 
ARE   AU-rich element 
AUF1   AU-binding factor 1 
Bp    Branch point 
bp   base pairs 
C/EBP   CCAAT enhancer binding protein 
cAMP   cyclic adenosine monophosphate 
CMV   human cytomegalovirus 
COX   Cyclooxygenases 
CUGBP1  CUG-binding protein 1 
Da    Dalton 
DAPI   4´,6-Diamidine-2´-phenylindole dihydrchloride 
DGCR8  DiGeorge syndrome chromosal region 8 
DMSO   Dimethylsufoxide 
DNA    Desoxyribonucleic acid 
dsDNA  double stranded DNA 
DSMZ    Deutsche Sammlung von Mikroorganismen und Zellkulturen 
dTTP    Desoxythymidintriphosphat 
EP   Prostaglandin E2 receptor 
eIF4F   Eukaryotic initiation factor 4F 
et al.   and others   
EDTA   Ethylenediaminetetraacetic acid 
EJC   Exon-junction complex 
ESE   Exonic splicing enhancer 
ESS   Exonic splicing silencer 
EZH2   Enhancer of Zeste homolog 2 
FCS   Fetal calf serum 
FLAP   5-Lipoxygenase activating protein 
GRE   GU-rich elements 
GSH   Glutathione 
hnRNP  heterogenous RNA-binding protein 
HuR   Human-antigen R 
IL-1β   Interleukin-1β 
ISS   Intronic splicing silencer 
KH   K homology domain 
LB   Luria broth 
LT   Leukotriene  
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LTC4S   Leukotriene C4 synthase 
MAPEG Membrane-associated proteins involved in eicosanoid and glutathione 
metabolism 
mg    Milligramm 
MGST   microsomal glutathione S transferase 
min    Minute(s) 
miRNA  microRNA 
mPGES-1  microsomal Prostaglandin E-synthase-1 
ml    Milliliter 
mRNA   messenger ribonucleic acid 
MTT   (3-(4,5-dimethythiazol-2-yl))-2,5-diphenyltetrazolium bromide 
NSCLC  non-small cell lung cancer 
ng    Nanogramm 
NCN   Nucleolin 
NMD   Nonsense-mediated mRNA decay 
NSAIDS  Non-steroidal anti-inflammatory drugs 
PABP   poly-(A)-binding protein 
PAGE   Polyacrylamide gelelectrophoresis 
PB   Processing-bodies 
PI   Prostacyclin 
PCR    Polymerase chain reaction 
PG   Prostaglandin 
PGE   Prostaglandin synthases 
PLA2   Phospholipase A2 
PTC   Premature termination codon 
rpm    rounds per minute 
RBD   RNA-binding domain 
RBP   RNA-binding protein 
REMSA  RNA electrophoretic mobility shift assay 
RISC   RNA-inducing silencing complex 
RNA    Ribonucleic acid 
RNP   Ribonucleoprotein 
RRM   RNA recognition motif 
RUST   regulated unproductive splicing and translation 
SBS   STAU1-binding site 
SDS   Sodium dodecylsulfate 
sec    Seconds 
SF   Splicing factor 
SMA   Spinal muscular atrophy 
snRNPs  small ribonucleoproteins 
SR   Serine/arginine-rich splicing factor 
SRE   Serum response element 
SS   Splice site 
ssDNA   single stranded DNA 
T   Time 
TM   Transmembrane 
TNFα   Tumour necrosis factor α 
TTP   Tristetraprolin 
TX   Thromboxane 
UPF1   Up-frameshift protein 1   
 Abbreviations                                  
 
7 
 
V    Voltage 
Tris    Tris-(hydroxymethyl)-aminomethan 
 
 List of Figures                         
8 
 
ΙΙ List of Figures 
 
Fig. 1: Schematic overview of the COX pathway and points of inhibition ..............................12 
Fig. 2: Crystal structure of mPGES-1 protein and proposed model of GSH transfer .............14 
Fig. 3: Overview of mPGES-1 protein homology between species and inhibitors .................15 
Fig. 4: PGE2 promotes cancer progression through induction of tumor epithelial cell 
proliferation, survival, migration and invasion .......................................................................16 
Fig. 5: Gene expression regulation in eukaryotes .................................................................18 
Fig. 6: Schematic model of the two transersterifications during splicing ................................19 
Fig. 7: Schematic representation of the structural changes of the spliceosome during splicing 
process. ...............................................................................................................................21 
Fig. 8: Different types of alternative splicing in eukaryotes ...................................................22 
Fig. 9: RNA-binding domains of RBPs ..................................................................................26 
Fig. 10: Schematic representation of CUGBP1 RNA-binding domains .................................28 
Fig. 11: Biogenesis of miRNAs .............................................................................................31 
Fig. 12: Essential characteristics of pri-miRNAs and mirtrons ...............................................32 
Fig. 13: Identification and characterization of a novel mPGES-1 3´UTR isoform ...................52 
Fig. 14: Quantification of CUGBP1 overexpression in A549 cells via Western Blot analysis .53 
Fig. 15: CUGBP1 binds selectively to GU-rich elements of mPGES-1 3´UTR ......................54 
Fig. 16: Quantification of CUGBP1 overexpression and mPGES-1 3´UTR reporter gene 
assay in HeLa cells ..............................................................................................................55 
Fig. 17: CUGBP1 is responsible for mPGES-1 3´UTR splicing .............................................56 
Fig. 18: mRNA decay of mPGES-1 3´UTR is UPF1 independent. ........................................57 
Fig. 19: Quantification of CUGBP1 knockdown in A549 cells via Western Blot analysis. ......58 
Fig. 20: Effect of CUGBP1 knockdown on mPGES-1 and COX-2 expression .......................61 
Fig. 21: Effect of CUGBP1 knockdown on induced mPGES-1 and mPGES-1 3´UTR 
expression in SF cells of RA patients ...................................................................................62 
Fig. 22: Cell viability of A549 cells analyzed by Trypan blue measurement ..........................63 
Fig. 23: Effect of CUGBP1 oe on IL-1β mediated induction of mPGES-1 expression. ..........64 
Fig. 24: CUGBP1 colocalizes with the PB marker DCP1a and PB formation is crucial for 
mPGES-1 protein translation ................................................................................................67 
Fig. 25: Effect of CUGBP1 overexpression and knockdown on IL-1β induced cell proliferation
 .............................................................................................................................................67 
Fig. 26: Expression levels and localization of CUGBP1 during time course experiment........68 
Fig. 27: Time course experiments in SF cells. ......................................................................69 
Fig. 28: Alignment of RNA sequences of GRE1, GRE2 and miR-574-5p ..............................70 
Fig. 29: CUGBP1 binds to mature miR-574-5p .....................................................................71 
Fig. 30: qRT-PCR analysis of miR-574-5p, mPGES-1 and mPGES-1 3´UTR mRNA 
expression in A549 cells .......................................................................................................72 
Fig. 31: Quantification via qRT-PCR analysis of 574-5p-mimcs mediated overexpression in 
A549 cells.............................................................................................................................72 
Fig. 32: Effect of miR-574-5p oe on mPGES-1 induction by IL-1β ........................................73 
Fig. 33: qRT-PCR analysis of LNA-mediated knockdown of miR-574-5p ..............................74 
Fig. 34: Influence of ∆miR-574-5p on induced mPGES-1 expression ...................................75 
 List of Figures                                  
 
9 
 
Fig. 35: Effect of miR-574-5p overexpression (20 pmol/µl) and knockdown (40 pmol/µl) on IL-
1β induced cell proliferation in A549 cells .............................................................................76 
Fig. 36: Cell proliferation in A549 cells treated with 10 µM mPGES-1 inhibitor (CIII) in 
combination with ∆CUGBP1 (20 pmol/µl) and miR-574-5p oe (20 pmol/µl) analyzed by MTT 
cell proliferation assay ..........................................................................................................77 
Fig. 37: Characterization of stable miR-574-5p oe A549 cell line ..........................................78 
Fig. 38: miR-574-5p increases mPGES-1 protein and PGE2 production ...............................79 
Fig. 39: miR-574-5p promotes tumour growth in vivo ...........................................................80 
Fig. 40: miR-574-5p expression is upregulated in tumours of NSCLC patients .....................81 
Fig. 41: Model of regulation of mPGES-1 expression in rheumatoid synovial fibroblasts. 
COX-2 and mPGES-1 are induced by stimulation of pro-inflammatory cytokines e.g. IL-1β .88 
Fig. 42: Model of the interaction between miR-574-5p and CUGBP1 on mPGES-1 
expression. ...........................................................................................................................91 
 
 
 
 
 
 
 
 
 
 
 
  
 List of Tables                                
10 
 
ΙΙΙ List of Tables 
 
Tab. 1: Sequence conservation of amino acids between the six CELF family members .......27 
Tab. 2: Cell density for different plate types ..........................................................................37 
Tab. 3: Standard PCR mastermix for Taq-polymerase or Q5-DNA polymerase* ..................41 
Tab. 4: Standard PCR program for Taq-polymerase or Q5-DNA polymerase* .....................41 
Tab. 5: Standard ligation ......................................................................................................42 
Tab. 6: Primers for cloning mPGES-1 3´UTR constructs ......................................................43 
Tab. 7: Primers for REMSA constructs .................................................................................43 
Tab. 8: Specific primers for qRT-PCR analysis using Sybergreen ........................................45 
Tab. 9: Dilution of antibodies ................................................................................................48 
Tab. 10: Dilutions of antibodies ............................................................................................49 
  
 1 Introduction                                   
11 
  
1 Introduction 
1.1 Prostaglandins – important lipid mediators in inflammation and cancer 
 
Inflammation is a biological response of tissues to harmful stimuli, like pathogens, damaged 
cells, or irritants and responsible for recruiting immune cells, blood vessels, and molecular 
mediators [1,2,3,4,5]. The function of inflammation is to eliminate the initial cause of cell 
injury, clear out necrotic cells and damaged tissues from the original insult, initiation of tissue 
repair and activation of inflammatory processes. Classical signs of inflammation are heat, 
pain, redness, swelling and loss of function [6,7,8,9,10]. During inflammation the 
prostaglandin (PG) cascade is activated by calcium signaling and cytokine-dependent 
enzyme inductions [11,12]. The group of eicosanoids is formed by PGs, leukotrienes (LTs), 
prostacyclins (PGIs) and thromboxanes (TXs) (Fig. 1). PGs represent a group of potent lipid 
mediators, formed by most cells in mammals acting as local hormones [13]. They exert 
complex functions as lipid signaling molecules mainly in cell growth, inflammation or 
immunity as well as messengers in the central nervous system. They derive from the 
precursor arachidonic acid (AA), a polyunsaturated fatty acid that is metabolized by various 
enzymes to a wide range of biologically and clinically important eicosanoids and its 
metabolites (Fig. 1). Phospholipase A2 (PLA2) is the main enzyme, which is responsible for  
AA cleavage, but it can also be generated from diacylglycerol by diacylglycerol lipase [14]. In 
the PG biosynthetic pathway, cyclooxygenases (COX)-1 and COX-2 catalyze the conversion 
of AA into the unstable intermediate PGH2 [15,16], which is subsequently converted by 
terminal synthases into physiologically important prostanoids PGE2, PGI2, PGD2, PGF2α, and 
TXA2. COX-1 is constitutively expressed in all human tissues and considered to play a role 
mainly in physiological PG production, while COX-2 is induced by pro-inflammatory agents 
and primarily detected at sites of inflammation [17]. Inhibition of PGE2 biosynthesis with non-
steroidal anti-inflammatory drugs (NSAIDs) [18] or specific inhibitors of COX-1 and COX-2 
activity (Coxibs), has been an important anti-inflammatory strategy for many years (Fig. 1). 
However, these drugs also cause serious side effects, such as gastrointestinal toxicity and 
kidney damage [19,20]. Several, but not all, clinical studies have revealed an increased rate 
of cardiovascular complications after long-term use of COX-2 inhibitors such as rofecoxib, 
celecoxib, and valdecoxib [21]. Despite significant variability of findings in these studies, the 
increased rates of myocardial infarction and stroke emerging from rofecoxib studies and 
cardiovascular complications found in celecoxib, some cancer prevention studies raise 
concerns about the cardiovascular safety of long-term treatment with selective Coxibs and 
 1 Introduction  
  
NSAIDS [22,23]. The severe cardiovascular side effects of COX
high risk for cardiovascular disease 
Fig. 1: Schematic overview of the COX pathway and points of inhibition. 
PGH2. Terminal synthases convert
receptor(s): EP1–EP4 = PGE2 recepto
and FP = PGF2α receptor. For inhibition of
1) can be targeted, modified [25]. 
It is known that selective inhibition of COX
to increased risk of thrombosis and
TXs/PGI2s balance [26]. PGI2 
by endothelial cells, which is blocked by COX inhibitors 
PGE2 synthases were identified as key enzymes in the biosynthesis of PGE
1.1.1 mPGES-1 – a member of 
 
The three PGE synthases, including cytosolic PGE synthase (cPGES), 
prostaglandin E synthase-1 
[11,29,30]. cPGES is localized in the cytosolic region in various cells and tissues under basal 
conditions and is functionally coupled with COX
production of PGE2 for the maintenance of h
p23, associates with numerous proteins, including heat shock proteins Hsp70 and Hsp
[29,31]. These complexes bind to genomic response elements in a hormone
manner. Overexpression of cPGES in cells suggests that this enzyme converts PGH
from COX-1, but not from COX
 
12 
-2 inhibitors are particularly 
[24]. 
AA is converted by 
 PGH2 into PGs and TXs. The bioactive lipids bind to their 
rs; DP1, DP2 = PGD2 receptors; IP = PGI2 receptor; TP = 
 PGE2 biosynthesis either COX or microsomal PG synthase
-2 has less gastrointestinal side effects, but leads 
 cardiovascular complications due to a disrupted 
is a potent inhibitor of platelet aggregation, mainly 
[27,28]. Recently
the MAPEG superfamily 
(mPGES-1), and mPGES-2, have been intensively studied 
-1. cPGES is most likely involved in the 
omeostasis [29]. Finally, cPGES, also known as 
-2, to PGE2, which is functionally linked to cPGES with COX
                                
 
COX 1/2 into 
respective 
TXA2 receptor 
-1 (mPGES-
synthesized 
, three terminal 
2.  
microsomal 
90 
-dependent 
2 derived 
-1 
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[29]. Also mPGES-2 is constitutively expressed in a wide variety of tissues and cell types and 
synthesized as a Golgi membrane-associated protein, contrary to mPGES-1 not inducible by 
pro-inflammatory stimuli [32]. There appears to be no differential coupling of mPGES-2 with 
the COX enzymes. Based on observations in mPGES-1 deficient mice, this enzyme and its 
product PGE2 are critically important mediators of pain, angiogenesis, fever, bone 
metabolism, and tumourigenesis [33,34,35,36,37], while cPGES or mPGES-2 seems to 
constitutively produce PGE2 possibly important for physiological reactions [32]. During 
inflammatory processes mPGES-1 can be induced in contrast to cPGES and mPGES-2 [11]. 
mPGES-1 acts downstream of COX enzymes and specifically catalyzes the conversion of 
PGH2 to PGE2 [11,38,39]. Based on amino acid sequence, size, hydropathy profile and 
membrane localization, mPGES-1 is classified as a member of the MAPEG (membrane-
associated proteins involved in eicosanoid and glutathione metabolism) superfamily [40]. The 
six human protein members of the MAPEG superfamily are 16-18 kDA integral membrane 
proteins, including mPGES-1, 5-lipoxygenase activating protein (FLAP), leukotriene C4 
synthase (LTC4S), and microsomal glutathione S transferase (MGST) 1-3. Multiple sequence 
alignments demonstrate six conserved amino acid sequences in the human members. The 
mPGES-1 has been characterized as an inducible, glutathione (GSH)-dependent membrane 
bound enzyme [11]. The primary structure of human, rat and mouse mPGES-1 demonstrated 
a high degree of amino acids sequence homology (>80%) [41]. Two amino acids are 
conserved in the MAPEG superfamily: Arg110, which is essential for the enzyme function 
and Tyr117 [42]. The mutation of Arg110 abrogates the catalytical function of mPGES-1, 
demonstrating the important role of this residue. Most recently, a crystal structure of mPGES-
1 was obtained through electron crystallography by Jegerschold et al. (Fig. 2) [43]. Three 
units of mPGES-1 form the active enzyme, which is dependent on GSH for its catalytic 
activity. The lipid substrate PGH2 binds together with GSH between transmembrane (TM) 
region one and four in neighboring subunits (Fig. 2) [43]. The gene of mPGES-1 (PTGES) 
maps to chromosome 9q34.11 and spans about 15 kb, divided into three exons. The putative 
promoter of the human mPGES-1 gene is GC-rich, lacks a TATA box and contains binding 
sites for CCAAT enhancer binding protein (C/EBP) α and β, two activator protein-1 (AP-1) 
sites, two tandem GC boxes, two progesterone receptors and three GRE elements, two 
cyclic adenosine monophosphate (cAMP) response elements and six serum response 
elements (SRE) [44]. mPGES-1 is expressed at minimal levels in most normal tissues, 
although abundant and constitutive expression is detected in a limited number of organs, 
such as the lung, kidney, and reproductive organs [45,46]. Clinical studies revealed an 
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increased expression of mPGES-1 protein in various types of cancer, including 
gastrointestinal, lung, stomach, brain, breast, pancreas, prostate and cervix carcinoma [37]. 
 
Fig. 2: Crystal structure of mPGES-1 protein and proposed model of GSH transfer. (A) mPGES-1 is 
composed of four TM regions connected by flexible loops. The trimer subunits have been colored in ribbon 
representation. Side view with the cytoplasmic side up. The TM helices of one subunit have been labeled at their 
C-terminal ends. (B) Suggested chemical mechanism for the mPGES-1 catalyzed PGE2 synthesis involves an 
attack of the GSH thiolate on the O9 of the endoperoxide bridge followed by proton donation to O11 via Arg-126. 
Arg-126 then abstracts a proton from C9 where a carbonyl forms as the oxygen sulfur bond is broken. The leaving 
GSH thiolate is stabilized by Arg-126, modified [43]. 
The mPGES-1 gene is inducible by various pro-inflammatory cytokines e.g. interleukin (IL) -
1β and tumor necrosis factor (TNF) α [11,47,48]. mPGES-1 is in general functionally coupled 
with COX-2 and its expression is often concomitantly induced with COX-2 overexpression, 
which contributes to the efficient generation of PGE2 during inflammatory processes [11]. 
However, different studies provided evidence that COX-2 and mPGES-1 can be 
independently regulated [49]. This observation suggests the possibility that the 
pharmacological targeting of mPGES-1 may result in the suppression of PGE2 production 
without causing severe cardiovascular side effects as traditional NSAIDs or selective COX-2 
inhibitors may do [50,51,52]. Therefore, mPGES-1 is a potential target for the development of 
novel anti-inflammatory drugs that can reduce symptoms of inflammation. Several selective 
inhibitors of mPGES-1 activity or expression have been identified and some of them have 
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been already evaluated in different 
them have been developed as anti
inhibitor MK-886 [55], and the active metabolite of another NSAID sulindac
to inhibit mPGES-1 with an IC
reported to inhibit mPGES-1 with micromolar IC
Leclerc et al. characterized a selective
studied its impact on the prostanoid profile in various
Compound III is a benzoimidazole, which has a submicromolar IC
recombinant mPGES-1. In cellular assays, it reduced PGE
macrophages and whole blood
former two systems [53]. Not many 
inhibition in cancer treatment
tumourigenesis [58]. The reasons for this are
and murine enzymes, which make
more difficult. Three amino acids in the
between human and rodent enzyme 
Fig. 3: Overview of mPGES-1 protein 
TM regions. Three amino acids in the active site of mPGES
(red) and rat/mouse (green) enzyme. These phylogenetic differences results
difference in the rodent enzyme, rendering most inhibitors developed for the human enzyme inefficient toward 
rat/mouse mPGES-1, modified [25]. 
Two additional amino acids are out
contribute to the human/murine inhibitor bindin
phylogenetic differences result
whereby most inhibitors developed for the human 
rodent mPGES-1. Inhibitors like Compound I
enzymes, are promising tools 
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preclinical inflammatory models [52,53,54]
-cancer agents. The COX-2 inhibitor NS
50 of 20, 1.6, and 80 µM, respectively. Leukotriene C
50, probably due to competing with GSH
 inhibitor of mPGES-1 activity (C
 models of inflammation
50 in both human and rat 
2 production in A549 cells, mouse 
 assay, causing a shunt to the prostacyclin pathway in the 
in vivo studies were performed on the effect
, although mPGES-1 and PGE2 have a cruci
 the phylogenetic differences between human
 research on the effects of mPGES-1 inhibition in cancer
 active site of TM4 of mPGES-1 are not conserved 
[59] (Fig. 3).  
homology between species and inhibitors. mPGES
-1, located in TM4 are not conserved between human 
 in a more restricted catalytic 
side of the active site and have also been proposed to 
g differences in a study
 in a more restricted catalytic difference in the rodent enzyme, 
mPGES-1 enzyme are 
II, active against both human and murine 
for further studies of mPGES-1 inhibition in vivo
                                
. So far none of 
-398 [48], FLAP 
 [48], were found 
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intracellular cAMP concentration. EP3 receptor mainly couples to Gi-proteins to decrease 
cAMP production. Responsible for the synthesis of the pro-tumourigenic PGE2 is mPGES-1. 
High levels of mPGES-1 were detected in many human cancer cell lines and tissues. 
Additional intermediate levels were observed in placenta, prostate, testis, and mammary 
gland [11]. PGE2 is over-produced at sites of inflammation and may be involved in many 
types of cancer, including bladder, breast, cervical, colorectal, esophageal, head and neck, 
skin, lung, oral, and prostate cancers [11,65]. As lipid mediator PGE2 can be distinguished 
from protein mediators e.g. cytokines. Lipid mediators are produced enzymatic from available 
precursors. Their levels can rapidly be increased while in contrast cytokine synthesis is 
slower, involving transcription and translation. Chronic inflammation can cause cancer 
suggesting NF-κB activation to be critically involved in tumourigenesis by initiating the 
expression of inflammatory genes, including those coding for the enzymes COX-2 and 
mPGES-1 [67,68]. The use of NSAIDs inhibiting COX isoenzymes has been shown to have 
cancer preventive effects in a large number of clinical trials demonstrating the tumour 
inducing properties of PGs [69]. The siRNA-mediated knockdown of mPGES-1 reduced the 
tumourigenic potential of DU145 and A549 cells in nude mice [70]. Recently, it was shown 
that genetic deletion of mPGES-1 reduced the synthesis of inducible PGE2 and markedly 
suppressed intestinal tumour formation in Apc∆14 mice [71]. Neither cell turnover nor β-
catenin expression was affected by mPGES-1 levels, suggesting the potent tumour 
suppressive properties were associated with impaired neovessel formation within the 
adenomas. PGE2 may be dominant in many types of cancer exerting tumouric properties 
[63,65]. However, not all PGs attribute a major pro-tumourigenic function [72,73]. Indeed, a 
study showed the shunting of tumour associated PG metabolism towards PGD2 due to 
deletion of mPGES-1 in colorectal cancer, which indicates that mPGES-1 deficient bone 
marrow derived cells (BMDCs) produce less IL-12 [74]. This appears maybe due to shunting 
of PG precursors down the PGD2 synthetic pathway in the absence of mPGES-1. Kapoor et 
al. demonstrated that mPGES-1 gene deletion resulted in diversion of prostanoid production 
from PGE2 to 6-keto PGF1α in a gene dose-dependent manner in heterozygous (Het) and null 
mouse embryonal fibroblasts (MEF) compared with their wildtype counterparts [75]. 
Eicosanoid profiling reveals shifting towards PGD2 pathway in mPGES-1 knockout mice [76]. 
Shunting of prostanoid synthesis towards PGD2 could potentially be one mechanism of 
immunomodulation in the absence of mPGES-1. The shunting of prostaglandins towards 
anti-tumourigenic metabolites as the immune suppressive role of PGD2 appears as highly 
desirable from the therapeutic point of view.  
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In contrast to this, PGE2 may also have tumour suppressive properties, occurred despite 
increased in cell turnover demonstrated by elevated thymidine incorporation [77]. These 
findings could not be reproduced by others assuming that the effect may have been 
environmentally influenced or perhaps the result of genetic changes occurring within the 
ApcMin mouse colony under study [78]. 
1.2 Post-transcriptional regulation of gene expression in eukaryotes 
 
The way from DNA to a functional active protein is a complex and strongly regulated cellular 
process (Fig. 5). The regulation of gene expression depends on a variety of mechanisms that 
can either increase or decrease the amount of gene products, such as transcriptional or 
translational control. During transcription the RNA is generated from a DNA template by RNA 
Polymerases. After transcription the RNA transcript is further processed (Fig. 5). The 
accessibility of large regions of DNA can depend on the chromatin structure that can be 
altered as a result of histone modifications directed by DNA methylation or DNA binding 
proteins [79]. Transcription by RNA Polymerases can be regulated by e.g. enhancers, 
silencers and activators. Enhancers are sites on the DNA helix that are bound by activators 
in order to loop the DNA bringing a specific promoter to the initiation complex. Silencers are 
regions of DNA sequences that, when bound by particular transcription factors, can silence 
expression of the gene. Stability, distribution and translation of transcribed mRNA can be 
regulated e.g. by the binding of RNA-binding proteins (RBPs) or microRNAs (miRNAs) to this 
mRNA. Genes can be switched on and off completely by means of these post-transcriptional 
mechanisms such as splicing, degradation, processing, export, capping and polyadenylation. 
However, a fine adjustment can also be carried out, which leads to the amplification or 
reduction of the expression of certain genes.  
 
Fig. 5: Gene expression regulation in eukaryotes. Eukaryotic transcription and translation is compartmentally 
separated, eukaryotic mRNAs must be exported from the nucleus to the cytoplasm, a process that may be 
regulated by different signaling pathways. 
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The spliceosome is a highly dynamic complex and consists of various factors that interact 
with the pre-mRNA and thereby bringing the reactive groups of the pre-mRNA into spatial 
proximity. Small-ribonucleoprotein U1 interacts through base pairing via the U1 snRNA with 
the 5´SS (Fig. 7 A). Splicing factor 1 (SF1) binds the adenosine of the BP and U2 auxiliary 
factor (U2AF) binds to polypyrimidine tract and the 3´SS. Next, the U2 snRNP binds to the 
branch point and forms the A complex. Then, the preassembled tri-snRNP (U4/U5/U6) is 
passed to the complex and forms the pre-catalytic B complex. By larger rearrangements of 
RNA-RNA and RNA-protein interactions, the binding of U1 and U4 triggers, at which the 
catalytically active B complex is formed, this takes the first step of catalysis. The second step 
takes place in the consequential complex C (Fig. 7 A). The spliceosome is resolved under 
adenosine 5´ triphosphate (ATP) consumption and recycled for the next round of splicing 
[93]. There exist alternative pathways at the early stages of spliceosome assembly. Most 
mammalian pre-mRNAs contain introns whose sizes varied from hundred to thousand 
nucleotides (nt), while their exons almost have a fixed length of only ∼120 nucleotides 
[94,95]. If introns are longer than 200-250 nts, a first complex on the exon is formed (Fig. 7 
B), this process is referred to as exon definition [96,97]. During exon definition, U1 snRNP 
binds to the 5´SS downstream of an exon and promotes the association of U2AF with the 
polypyrimidine tract at 3´SS upstream of this exon. This leads to the recruitment of the U2 
snRNP to the BP. Splicing enhancer sequences within the exon (ESE) recruit proteins of the 
serine/arginine-rich splicing factor (SR) protein family, which establish a network of protein–
protein interactions across the exon that stabilize the exon-defined complex [98,99]. 
Splicing can occur during transcription (co-transcriptional) or after transcription (post-
transcriptional) [100,101]. This difference is functionally important as co-transcriptional 
splicing can regulate splicing by diverse transcription-dependent mechanisms, whereas post-
transcriptional splicing might allow additional regulatory mechanisms to operate or couple 
splicing with other downstream events [102].  
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Fig. 7: Schematic representation of the structural changes of the spliceosome during splicing process
The snRNPs are shown as circles and the exons
interactions occurring during exon definition
1.2.2 Alternative splicing  
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particular tissues, and omitted from the mRNA in others [92]. AS can be divided into four 
types: cassette exons, alternative 3´SS and 5´SS and intron retention (Fig. 8). The most 
prominent types are cassette exons, that are either included in the mature mRNA (inclusion) 
or not (exclusion) [105,106,107]. In certain cases, these exons can occur as mutually 
exclusive exons. Always one of these exons is included, but not both. Furthermore, different 
5´ or 3´SS can extend or shorten exon length. Alternative 3´SS and 5´SS selection account 
for 18.4% and 7.9% of all AS events in higher eukaryotes, respectively [107]. A retained 
intron is not spliced and included in the mature mRNA. All four types can occur in both the 
coding and non-coding area. Alternative exons contain the same conserved regions as 
constitutive exons, but differ in their strength of their splices sites. The consistency of the 
5´SS sequence with the consensus sequence GURAGU is crucial, as the splice site is 
weaker the more the sequence differs [108]. In general alternative exons have a weaker 
5´SS, moreover, they are shorter and the branch point is located further upstream. AS 
underlies the control of associated protein factors with specific pre-mRNA sequences, 
thereby regulating the course of spliceosome assembly and splice site usage. 
 
Fig. 8: Different types of alternative splicing in eukaryotes. In the figure, constitutive exons are shown in gray 
and alternatively spliced regions in yellow. Introns are represented by solid lines, and dashed lines indicate 
splicing options, modified [106]. 
RNA processing and AS are important either for generating protein diversity and modulating 
levels of protein expression or regulating post-transcriptional mechanisms [92]. Important 
mediators of AS are RBPs that have been shown to control AS [109,110]. Exons and introns 
contain short, degenerate binding sites for splicing auxiliary proteins. The classical splicing 
regulators are SR proteins (SR1-12), which, when bound to exonic sequences known as 
exonic splicing enhancers (ESEs), tend to promote exon inclusion. Exon exclusion is 
mediated by heterogeneous RNPs (hnRNPs) binding to exonic splicing silencers (ESSs) 
and/or intronic splicing silencers/enhancers (ISSs/ISEs) [110,111,112]. Many hnRNPs 
alternate between the nucleus and the cytoplasm to exert their various functions. Besides 
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their function in splicing they play a role in transcription, mRNA stability, mRNA export and 
translation [113,114,115]. 
Defects in splicing are often correlated with diseases and involved in the progression of 
cancer [116]. At least 15% of all human diseases are due to aberrant splicing, e.g. spinal 
muscular atrophy (SMA) [117,118]. Most of them are point mutations in the consensus 
sequences within splice sites. It is estimated that up to 50% of disease-causing mutations in 
exons affect splicing. Due to mutations, exon skipping or premature termination codon (PTC) 
insertion into the mRNA can occur, resulting in non-functional proteins. Aberrant splicing has 
been shown to promote tumour cell proliferation which is often associated with deregulated 
expression of splicing factors or aberrant splicing of tumour suppressors [119,120].  
1.2.3 Nonsense mediated mRNA decay 
 
Alternative pre-mRNA splicing is a fundamental regulatory process for most mammalian 
multi-exon genes to increase proteome diversity. Nonsense mediated mRNA decay (NMD) is 
the best characterized mRNA surveillance mechanism in eukaryotes which provides an 
important way of controlling mRNA quality and expression. NMD functions in at least two 
distinct cellular processes. First the downregulation of abnormal mRNA transcripts that are 
generated as a consequence of routine errors in gene expression, and second to maintain an 
appropriate level of gene expression by downregulating physiological mRNAs in response to 
changes in cellular environment. One function is to reduce errors in gene expression by 
eliminating mRNA transcripts that harbor PTCs. PTCs situated more than ~50-55 nucleotides 
upstream of an exon-junction-complex (EJC) generally trigger NMD [121]. Transcripts that 
contain PTCs can arise from transcription of pseudo genes, nucleotide disincorporation 
during transcription of bona fide genes, or more frequently due to processing errors during 
the post-transcriptional maturation of the primary transcript [122,123]. In fact, PTCs shorten 
the length of the coding region and any downstream EJCs that normally are localized within 
the coding region fail to be removed from what becomes the 3´UTR. Further, NMD is a key 
control step, conserved in eukaryotes. It prevents the synthesis of C-terminal truncated 
proteins, which probably leads to protection of the cell from resultant destructive effects 
[123,124,125]. The fact that 30% of inherited genetic diseases are due to PTC accentuates 
the biological importance of NMD [126,127]. Generally, NMD is thought to play a protective 
role, by destroying truncated transcripts, but it also regulates gene expression through AS 
coupled with NMD (AS-NMD) [128,129,130]. AS-NMD is better known as a negative 
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feedback control mechanism to maintain homeostatic expression of RBPs and splicing 
regulator [131,132]. It has been shown that several splice factors, including SR proteins, 
regulate splicing of their own pre-mRNA [133,134,135]. In this mode of negative feedback 
loop regulation, high levels of the SR cause its own pre-mRNA splicing into an unproductive 
isoform and followed by degradation, which results in lower protein levels [134]. Lewis et al. 
have named this process regulated unproductive splicing and translation (RUST) [136,137]. 
It seems that 10-15% of human transcripts can be switched off by NMD coupled to AS [136]. 
Since NMD isoforms are not effectively translated into proteins, switching between the 
translational isoform and the NMD isoform allows alternative splicing to control overall 
abundance of the transcript and protein [131,132,137,138]. Finally, the NMD pathway has 
also been reported to modulate the expression of several normal genes by mechanisms 
involving the presence of an upstream open reading frame or an intron in the 3´UTR, both of 
which are predicted to elicit NMD [129,139,140]. Whether this is used in a regulatory context 
is not fully understood, but it has been proposed that different tissues display different 
efficiencies of NMD, which in turn may lead to tissue specific differences in mRNAs 
containing NMD features [141]. 
There are further mRNA quality control mechanisms termed non-stop decay, which appear 
when mRNAs lack a termination codon and the no-go decay, occurring when mRNA 
translation elongation stops [142,143,144]. Staufen1 (STAU1)-mediated mRNA decay (SMD) 
is an mRNA degradation process in mammals that is mediated by the binding of STAU1 to a 
STAU1-binding site (SBS) within 3´UTR of target mRNAs [145]. During SMD, STAU1, a 
double-stranded RNA-binding protein, recognizes dsRNA structures formed either by 
intramolecular base-pairing of 3´UTR sequences or by intermolecular base-pairing of 3´UTR 
sequences with a long noncoding RNA via partially complementary [146]. 
1.3 RNA-binding proteins 
 
RNA-binding proteins are proteins that bind specifically to target RNA molecules. They play a 
key role during gene expression and RNA processing [147]. Due to their specific binding they 
have also a crucial role in various cellular processes. They are generally found in the 
cytoplasm and nucleus and involved in post-transcriptional processes including RNA splicing, 
editing, stability and transport [148,149,150]. However, often more than one RBP has the 
capacity to bind to a specific sequence on the target RNA [151]. Cellular RNAs are always 
associated with RBPs to form high dynamic ribonucleoprotein (RNP) complexes [152,153]. 
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This interaction begins during transcription as some RBPs remain bound to RNA until 
degradation. Others in contrast only transiently bind to RNA to regulate RNA splicing, 
processing, transport, and localization. The composition and recruitment of RNPs varies 
depending on mRNA localization and processing level [154]. Their remodeling allows 
adjustments in gene expression under conditions requiring adaptive changes. Dysfunction of 
RBPs is often linked to disease which reflects the relevance of protein-RNA interactions in 
cellular homeostasis [155].  
RNA-binding proteins exhibit highly specific recognition of their target RNAs by recognizing 
their sequences and structures. Although all RBPs bind RNA, they do so with different RNA-
sequence specificities and affinities. The latter is mediated by a relatively small number of 
RNA-binding scaffolds whose properties are further modulated by auxiliary domains. 
Normally, RBPs contain one or more RNA binding and auxiliary domains. The auxiliary 
domains can also mediate the interactions of the RBP with other proteins and, in many 
cases, are subject to regulation by post-translational modification. Hence, cells can generate 
numerous RNPs whose composition and modeling of individual components is unique for 
each mRNA. The RNPs are further remodeled during the maturation of the mRNA into its 
functional form. Further, diversity of RBPs is achieved by post-translational modifications. 
Three types of modifications have been described: phosphorylation, arginine methylation and 
small ubiquitin-like modification [156,157,158]. Most of the RBPs discovered over the last 
three decades match the classical view of RBP architecture with a modular combination of 
well-characterized RNA-binding domains (RBDs) such as the RNA recognition motif (RRM), 
the K homology domain (KH) and the DEAD box helicase domain (Fig. 9). Single RBD can 
bind short stretches of RNA, typically 2–6 nucleotides [159]. RBPs usually build their affinity 
and specificity for RNA on the cooperative function of multiple classical RBDs as exemplarily 
illustrated by the four RRMs that work together in nucleolin (NCL) or the poly(A)-binding 
protein. There is evidence that RBPs play a crucial role in tumour development and 
progression [160]. Aberrant expression and regulation of RBPs results in misregulation of 
splicing observed in cancer [161,162]. Many RBPs are differentially expressed in different 
cancer types for example KHDRBS1 (Sam68), ELAVL1 (HuR) and FXR1 [163,164,165]. For 
some RBPs, the change in expression levels are related with copy number variations e.g. 
CELF3 in breast cancer, RBM24 in liver cancer, IGF2BP2, IGF2BP3 in lung cancer or copy 
number losses of KHDRBS2 in lung cancer [166]. Some expression changes are caused by 
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mutations on these RBPs for example SF3B1, SRSF2, RBM10, U2AF1, SF3B1, PPRC1, 
RBMXL1, or HNRNPCL1 [167,168,169,170,171].  
 
Fig. 9: RNA-binding domains of RBPs. Different RNA-binding domains include the RNA-binding domain (RBD), 
K-homology (KH) domain, RGG (Arg-Gly-Gly) box, double stranded RNA-binding domain (dsRBD), 
Piwi/Argonaute/Zwille (PAZ) domain, RNA helicase DEAD/DEAH box, RNA-binding zinc finger (ZnF) and Puf 
RNA-binding repeats (PUF), modified  [172]. 
1.3.1 AU-rich and GU-rich elements  
 
Generally the 3´UTRs are conserved through species. Transcripts harbor specific motifs that 
serve as binding sites for RBPs and thereby they regulate mRNA stability and translation. 
They contain various cis-acting regulatory elements that are specifically recognized by 
binding elements, usually RBPs or RNAs, termed trans-acting factors. The interplay between 
both is crucial for the post-transcriptional regulation of gene expression. The adenylate 
uridylate (AU) rich elements (AREs), often characterized by AUUUA pentamers, are the most 
common regulatory elements in the 3´UTR of mRNA. They influence mRNA stability, 
translation and alternative pre-mRNA processing. Their presence is typical for short-lived 
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mRNAs. AREs are recognized by ARE-binding proteins (ARE-BPs). It depends on the 
binding RBP how the mRNA is regulated. RBPs e.g. from the ELAV protein family or HuR 
enhance mRNA stabilization and translation, in contrast to e.g. tristetraprolin (TTP) or AU-
binding factor 1 (AUF1) that are responsible for mRNA destabilization and translational 
repression [173,174,175].  
A global assessment showed that 5% of the human mRNAs harbor GU-rich elements 
(GREs) in their 3´UTRs that are highly conserved through species [83]. Furthermore, they 
exist in groups of 2 to 5 overlapping GUUUG pentamers. GREs are functionally linked to 
rapid mRNA decay in short-lived transcripts and contribute to regulation of deadenylation, 
mRNA decay and pre-mRNA splicing [176,177]. Recently, proteins from the CELF family 
have been identified to recognize GREs [178]. 
1.3.2 CUGBP1 – a prominent member of the CELF family  
 
There are six CELF proteins CELF1-6 of the CELF family that can be separated by sequence 
similarity into two subgroups CELF1-2 and CELF3-6 (Tab. 1). The RBPs CUG-binding 
protein 1 (CUGBP1), also called ELAV-like family member 1 (CELF1) and CELF2 
(Embryonic lethal abnormal vision Type RNA-binding protein, ETR-3, CUGBP2) are the most 
relevant members of the CELF family that bind to (CUG)8 RNA nucleotides [109,179].  
           Tab. 1: Sequence conservation of amino acids between the six CELF family members [180] 
  CELF1 CELF2 CELF3 CELF4 CELF5 CELF6 
CELF1 100 76 45 42 44 43 
CELF2  100 43,5 43 45 46 
CELF3   100 61 62 64 
CELF4    100 63,5 65 
CELF5     100 64,5 
CELF6      100 
 
Along with HuR, CUGBP1 is a prototypic member of a family of RBPs that are known as the 
CUGBP and ELAV-like family proteins. These RBPs regulate a network of transcripts that 
control important cellular functions such as cell growth and apoptosis by binding to target 
transcripts. Each member of the family of CELF proteins contains three RBDs that bind to 
RNA, two in the N-terminal and one in the C-terminal region (Fig. 10). The RBDs show high 
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sequence similarity but the sequence of the linker between RBD2 and RBD3 is less well 
conserved. RBD1 and RBD2 are separated by a short spacer and critical for the CUGBP1 
interaction with all examined RNAs.  
 
Fig. 10: Schematic representation of CUGBP1 RNA-binding domains (RBDs), modified [181]. CUGBP1 
consists of three RBDs separated by spacers. The key amino acids which regulate intracellular localization of 
CUGBP1 (S28), translational activity of CUGBP1 (S302), and stability of CUGBP1 are shown on the bottom. The 
amino acids for the phosphorylation of CUGBP1 by PKCδ were found by the prediction program. 
RBD3 is separated from the first two RBDs by a long linker region, which seems to be 
important for the regulation of RNA binding activity of CUGBP1 and for regulation between 
the interactions of CUGBP1 with other proteins. Although, CUGBP1 and 2 have 76% 
identical protein sequences and share almost identical RBPs they play different roles in post-
transcriptional regulation on genes [180]. CUGBP2 stabilizes mRNA, whereas CUGBP1 acts 
as destabilization factor [182]. However, the effects of both proteins are cell type specific and 
depend on cellular conditions. CUGBP2 is mostly expressed in heart, skeletal muscle and 
brain, while CUGBP1 is ubiquitously expressed [183,184,185]. Both are localized in the 
cytoplasm as well as the nucleus [109,184,186,187]. These dual locations also suggest that 
these CELF proteins are multifunctional proteins implicated in molecular processes specific 
to each cellular compartment. Indeed a role in control of AS and translational regulation has 
been described [188,189,190,191].  
The binding sites for CELF proteins are usually U-rich, although binding sites may contain 
other nucleotides like A or G. CUGBP1 and CUGBP2, almost identical in their RNA-binding 
domains, play different roles in post-transcriptional mRNA regulation. It has been 
demonstrated that CUGBP2 also binds to AREs, is sufficient to block C to U RNA editing of 
Mammalian apolipoprotein B (apoB) transcripts and is necessary for repression of apoB 
editing in cells [192]. Furthermore, CUGBP2 stabilizes and inhibits translation of COX-2 
mRNAs by direct interaction with AREs in the 3´UTR [193]. In addition to the canonical 
GREs, CUGBP1 binds to U-rich, GU-rich sequences, or GU-repeat sequences within pre-
mRNA introns or mRNA 3’UTRs. It is known that CUGBP1 regulates alternative splicing by 
binding to a U/G rich sequence element in the pre-mRNA [194,195]. It has been shown that 
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overexpression of CUGBP1 in a normal fibroblast cell line induced a strong intron retention in 
human specific chloride channel (CIC-1) [188]. In addition to its role as splice factor CUGBP1 
has an important role in the control of mRNA translation and or stability by association with 
specific sequence motifs in the 3´UTR [195,196]. CUGBP1 can control translation either by 
acting at the 5´end of the mRNA via a G/C-rich element or mRNA deadenylation and hence 
degradation via a GU-rich element located in the 3´UTR. Two mRNAs were identified to bind 
CUGBP1 to sequence specific elements in their 5´UTR region. These are the C/EBPβ and 
p21 mRNAs [197,198,199]. C/EBPβ mRNA encodes a transcription factor belonging to a 
family of proteins that bind the enhancer CCAAT and it plays an important role in hepatocyte 
growth and differentiation [200]. Binding specificities, localization and functions of CUGBP1 
are dependent on the different phosphorylation states of CUGBP1 [201] [202,203]. CUGBP1 
has to be hyperphosphorylated for binding to the G/C rich element of p21 and C/EBPβ 
mRNAs [200,204]. In contrast, the deadenylation activity to GREs is activated by 
dephosphophorylation [202]. Additionally, CUGBP1 is functionally linked to mRNA translation 
in processing-bodies (PBs). Yu et al. described the role of CUGBP1 as translational 
repressor. They demonstrated that the repression of occludin translation by CUGBP1 was 
due the colocalization of CUGBP1 and occludin RNA in P-bodies (PBs) [151].  
Abnormalities in RNA metabolism and AS are important players in complex disease 
phenotypes. It is known that CUGBP1 binds to (CUG)8 containing RNA motifs. DM1 is 
genetically linked to a CUG expansion in 3´UTR of Dystrophia Myotonica protein kinase 
(DMPK). The overexpression of CUGBP1 has been reported in myotonic dystrophy type 1 
(DM1) myoblasts, the heart, esophageal epithelial cells, skeletal muscle tissues, NSCLC, 
and some DM1 mouse model [204]. In addition to its role in embryonic and cardiac 
development, skeletal muscle and adipose tissue differentiation, and germ cell formation, 
CUGBP1 plays an important role tumour genesis [205,206,207,208,209]. 
1.4 miRNAs 
 
miRNAs represent a new class of single-stranded RNAs of 18–22 nucleotides, which play a 
key regulatory role in gene expression at the post-transcriptional level [210]. They are 
conserved across species, expressed across cell types and active against a large proportion 
of the transcriptome. Since their discovery miRNAs have been shown to be involved in a 
wide range of biological processes such as cell cycle control, apoptosis and several 
developmental and physiological processes including stem cell differentiation, hypoxia, 
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cardiac and skeletal muscle development [211,212,213]. Furthermore, highly tissue-specific 
expression patterns and distinct temporal expression changes during embryogenesis 
suggest that miRNAs play a key role in the differentiation and maintenance of tissue identity. 
In addition to their important roles in healthy individuals, miRNAs have also been implicated 
in a number of diseases including cancer, heart diseases and neurological diseases.  Lin-4 in 
Caenorhabditis elegans was the first identified miRNA. Lee et al. discovered that the lin-4 
gene did not encode a protein but rather a short non-coding RNA that contained sequences 
partially complementary to multiple sequences in the 3´UTR of the lin-14 mRNA [214]. Lin-4 
regulates lin-14 gene expression by complementarily binding through base-pairing in the 
3´UTR of the lin-14 mRNA and reduces the translation of the mRNA.  
1.4.1 Biogenesis and regulation of miRNAs 
 
Initially, canonical miRNA genes are transcribed into long primary transcripts (pri-miRNA) by 
RNA polymerase II (Fig. 11) [215]. The transcripts contain one or more hairpins, and the 
miRNAs are located in the double-stranded stem. RBP DiGeorge syndrome chromosomal 
region 8 (DGCR8) recognizes the pri-miRNA and cleaves it by interacting with the RNAse III 
Drosha [216,217]. This functional interaction of DGCR8 and Drosha is termed as 
microprocessor complex [218] (Fig. 11). Drosha cleaves at the basis of the hairpin within the 
pri-miRNA, resulting in a ∼70 nt long hairpin molecule. This precursor miRNA (pre-miRNA) 
carries a two-nucleotide 3′ overhang of the RNase III-mediated cleavage that is recognized 
by the nuclear export factor Exportin-5 [219]. The pre-miRNA is exported to the cytoplasm by 
Ran-GTP dependent Exportin-5. In the cytoplasm, the RNase III enzym Dicer cleaves the 
pre-miRNA in complex with the double-stranded RNA-binding protein TRBP resulting in a 
double-stranded miRNA duplex [220,221]. Characteristically the duplex is 18–22 nt long, with 
one guide and a passenger strand. The guide strand is incorporated into the RNA-induced 
silencing complex (RISC), a large multiprotein miRNA ribonucleoprotein complex that is the 
effector compound in modulating target gene transcription. The RISC complex contains 
members of the Argonaute (Ago) protein family. They have an endonuclease activity directed 
against mRNA strands that are complementary to their bound miRNA fragment.  
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Fig. 11: Biogenesis of miRNAs. miRNAs are transcribed as pri-miRNAs by RNA-polymerase II. The pri-miRNAs 
are processed by Drosha into 70 nt long pre-miRNAs. Exportin-5 recognizes the structure and exports the pre-
miRNA from the nucleus to the cytoplasm. Dicer processes the pre-miRNA into an imperfect double strand. The 
mature miRNA is incorporated into the RISC complex which is formed out of Ago proteins. The miRNA binds to 
the target mRNA where it can either regulate mRNA degradation, translational repression or deadenylation. 
Mirtrons are alternative precursors for miRNA biogenesis. The short hairpin introns use splicing to bypass Drosha 
cleavage, which is otherwise essential for the generation of canonical animal miRNAs, modified  [222] 
Selection of the guide strand from the dsRNA appears to be based primarily on the stability 
of the termini of the two ends [223]. The strand with lower stability base pairing of the 2–4 nt 
at the 5´-end of the duplex preferentially associates with RISC and thus becomes the active 
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miRNA. The guide strand is selected by Ago protein on the basis of stability of the 5´-end 
[223]. The remaining passenger strand is degraded as a RISC complex substrate. After 
integration into the active RISC complex, miRNAs exert their regulatory effects by binding to 
imperfect complementary sites within the 3´UTR of their mRNA targets. The formation of the 
double-stranded RNA, resulting from the binding of the miRNA, leads to translational 
repression. 
A subclass of miRNAs, termed mirtrons, derives from short introns and enter the miRNA 
biogenesis pathway as Dicer substrates (Fig. 11). Mirtrons were first identified in Drosophila 
melanogaster and C. elegans and are a type of miRNAs that are located in the introns of the 
mRNA encoding genes [224,225]. Mirtrons are alternative precursors for miRNA biogenesis 
(Fig. 12). The short hairpin introns use splicing to bypass Drosha cleavage, which is 
otherwise essential for the generation of canonical animal miRNAs. Mirtrons are short 
intronic miRNA precursors representing an alternative, Drosha/DGCR8-independent miRNA 
biogenesis pathway, which relies on mRNA splicing and lariat debranching for the formation 
of pre-miRNA. The refolded stem loop pre-miRNA can be further processed by Dicer into 
mature miRNA and functions like classical miRNAs regulating gene expression, by either 
mRNA destabilization, inhibition of the translation or target mRNA cleavage [226]. 
                    
Fig. 12: Essential characteristics of pri-miRNAs and mirtrons [225] 
It has been further demonstrated that miRNAs can be processed independently of Dicer. For 
example Ago2, can directly cleave miRNA precursors into mature miRNAs [227]. A third 
biogenesis strategy, similar to mirtron biogenesis, initiates from short introns (80-100 nt) but 
bypasses Dicer cleavage [228]. These short introns, termed as agotrons, are associated with 
 1 Introduction                                   
33 
  
and stabilized by Ago proteins in the cytoplasm. Some agotrons are completely conserved in 
mammalian species, suggesting that they are of great functional importance. 
1.4.2 Post-transcriptional gene regulation of miRNAs 
 
In general, miRNAs post-transcriptionally regulate protein synthesis by base-pairing to par-
tially complementary sequences in the 3´UTRs of target mRNAs but binding sites can also 
occur within the 5´UTR or the coding region [229,230,231], thus a plenty of mRNAs can be 
regulated by the same miRNA. The most common feature is perfect base-pairing between 
nucleotides 2 and 7 at the 5´end of the miRNA (seed region) and the target site. The miRNAs 
mediate mRNA repression by recruiting the miRNA-induced silencing complex (miRISC), a 
ribonucleoprotein complex, to target mRNAs. The core of the miRISC contains a miRNA-
loaded Ago protein and GW182 [229]. The exact composition of the miRNA complex as well 
as the mechanisms used to control target gene expression are still uncertain. In animals 
miRNAs usually base-pair to their target mRNAs with imperfect complementarity, which 
predominantly leads to translational repression, although this may also induce mRNA 
destabilization [232,233]. However, several other mechanisms have been documented, 
including translational inhibition at the level of initiation and elongation, rapid degradation of 
the nascent protein and mRNA degradation. Vilmalraj et al. identified that the SMAD specific 
E3 ubiquitin protein ligase 1 (Smurf1) 3´UTR is directly targeted by miR-15b by that miR-15b 
promotes osteoblast differentiation by indirectly protecting transcription factor Runx2 from 
Smurf1 mediated degradation [234]. In this case miR-15b acts as a positive regulator for 
osteoblast differentiation. Stimulation of gene expression via a decoy mechanism was 
previously found for another miRNA, miR-328 [235,236]. It was shown that miR-328 acts as 
miRNA decoy for the poly(rC)-binding protein hnRNP E2, a global splicing factor and 
translation repressor thereby regulating myeloid cell differentiation. During monocyte 
maturation miR-328 was upregulated and antagonized hnRNP E2 which then leads to 
increased ROS production as well as monocyte adhesion and migration. Hence, the balance 
between hnRNP E2 and miR-328 is cruicial for hnRNP E2 inhibition and the concomitant 
upregulation of the expression of hnRNP E2 target genes.  
1.4.3 Role of miRNAs in cancer and tumour development 
 
Numerous studies demonstrated a highly specific miRNA expression profile during particular 
stages of tumour development. In particular, miRNAs are implicated in the process of 
stimulation of cellular invasion and metastasis, as well as predictors of poor prognosis of 
 1 Introduction                                   
34 
  
breast cancer and lung cancer [237,238,239]. This indicates that miRNAs are a new class of 
genes involved in tumourigenesis [240]. Recent findings have linked the miRNA processing 
machinery to cancer pathogenesis. First, Dicer and Ago were found deleted in a certain 
subset of tumours, and Dicer protein levels were found to be reduced in poorly differentiated 
lung tumours with a significant impact on patient survival [241,242]. When cells exhibit 
abnormal growth and loss of apoptosis function, it usually results in cancer development and 
progression. Several recent studies indicate that miRNA regulates cell growth and apoptosis 
[212]. The expression of some miRNAs is decreased in cancer cells. These types of miRNAs 
are considered tumor suppressor genes. B cell chronic lymphocytic leukemia (CLL) is the 
most common adult leukemia in the western world and highly associated with loss of 
chromosomal region 13q14 [243]. It was demonstrated that expression of miR-16 and miR-
15a was abolished or lost in 68% of CLL cases [244]. The tumor suppressing properties of 
these miRNAs are contributed to abnormal Bcl2 expression, an anti-apoptotic protein, which 
is overexpressed in CLL and thereby promoting cell survival [245]. Emerging evidence 
suggests that miR-let-7 may play a critical role in the pathogenesis of lung cancer [246]. In 
this study they observed reduced expression levels of miR-let-7 in both in vitro and in vivo 
lung cancer and they also observed that overexpression of miR-let-7 in A549 cell inhibited 
cancer cell growth. miR-let-7 negatively regulates the expression of rat sarcoma (RAS) and 
MYC by targeting their mRNAs for translation repression due to multiple complementary sites 
to miR-let-7 in their 3´UTR [247]. RAS and MYC have been implicated, together with p53, as 
important oncogenes in lung cancer. In lung cancer tissue levels of miR-let-7 were reduced 
whereas RAS protein was increased, suggesting miR-let-7 regulation of RAS as a 
mechanism for lung oncogenesis [247]. In contrast to miR-let-7, the expression of miRNA 
cluster miR-17–92 is significantly increased in lung cancer [248]. The cluster was shown to 
enhance cell growth in lung cancer. Interestingly, two predicted targets of the miR-17–92 
cluster are two tumor suppressor genes PTEN and RB2. Whether the miR-17–92 is cluster 
directly involved in lung cancer development or controls lung cancer by targeting lung cancer 
suppressor genes is still unknown. Moreover, miR-19 has been identified as potent 
oncogene of the miR-17-92 cluster. It was shown that miR-19 promotes cellular growth and 
cancer by inhibiting the expression of phosphatase and tensin homolog (PTEN), a tumour 
suppressor [249]. miR-19 activates the Akt–mTOR pathway, thereby functionally 
antagonizing PTEN to promote cell survival. Recently, it was shown that the expression and 
function of the histone methyltransferase oncogene enhancer of zeste homolog 2 (EZH2) in 
cancer cell lines is limited by miR-101 [250,251,252]. Other links in cancer related miRNA 
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expression have been demonstrated by Michael et al, who showed that miR-143 and miR-
145 are reduced in colorectal cancer [253]. However, the transcriptional level of the 
precursors of miR-143 and miR-145 was not altered in precancerous and neoplastic 
colorectal tissue, suggesting that altered transcription is not responsible for the reduced 
mature miRNA levels. These and other data show the important role of miRNA expression 
levels in the pathogenesis of human cancer. 
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2 Aims of this study 
 
One of the key enzymes in the induced PG biosynthesis is mPGES-1. In the last decades it 
turned out that mPGES-1 and its product PGE2 are crucial for tumour development and 
tumour progression. The promoter alone cannot account for the strong upregulation in these 
types of cancer. Until now nothing is known about post-transcriptional regulation of   
mPGES-1 by miRNAs or alternative splicing. Alternative splicing is a powerful mechanism of 
mammalian cells to regulate gene expression. However, dysregulation in splicing processes 
often correlates with diseases and tumour progression. Therefore, splicing patterns in 
different well-established cell lines for characterizing mPGES-1 were analyzed. The 3´UTR of 
mPGES-1 contains two GREs which could function as regulatory elements [254]. Recently, it 
was shown that GREs are binding sites for CUGBP1 [195]. To prove if mPGES-1 is 
regulated by CUGBP1, reporter gene assays, RT-PCR and REMSAs were performed. 
Furthermore, CUGBP1 has been demonstrated to act as potential destabilizing factor [177]. 
To address these issues, levels of CUGBP1 were manipulated in A549 and SF cells. 
Recently, it was demonstrated that besides its canonical function miR-328 is able to act as 
RNA decoy to hnRNP E2 [235]. Interestingly, mature miR-574-5p harbors GREs 
representing bona fide CUGBP1 binding sites. To address this mode of action, REMSAs 
were performed and miR-574-5p levels were manipulated. miR-574-5p was discovered as 
novel serum-based biomarker for early-stage NSCLC [239], therefore miR-574-5p levels in 
NSCLC tissues were analyzed. Furthermore, miR-574-5p enhances tumour progression via 
downregulating the checkpoint suppressor gene 1 in human lung cancer [255]. The 
tumourigenic properties of miR-574-5p were addressed by in vivo experiments in CD1 nude 
mice. 
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3 Materials & Methods 
3.1 Cell culture 
3.1.1 Cell types and cell culture conditions 
 
The human lung adenocarcinoma cell line A549 (ATCC Manassas, VA, USA) and the 
cervical cancer cell line HeLa (DMSZ) were cultured in Dulbecco’s modified Eagle medium 
(DMEM, Life technologies) with 10% (v/v) heat inactivated fetal bovine serum (Life 
technologies), 100 U/ml penicillin (PAA the Cell Culture Company) 100 µg/ml streptomycin 
(PAA the Cell Culture Company) and 1 mM sodium pyruvate (PAA the Cell Culture 
Company). Synovial fibroblasts of RA patients (kindly provided by Prof. P.-J. Jakobsson and 
Heidi Wähämaa) were cultured like A549 cells in 10% (v/v) heat inactivated fetal bovine 
serum (Sigma), additionally with 10 mM HEPES (Sigma Aldrich). A549 and HeLa cells were 
grown in T75 cell culture flasks under standard growth conditions (humidified atmosphere of 
5% CO2 at 37°C). SF cells were grown in T125 cell culture flasks under standard growth 
conditions (humidified atmosphere of 5% CO2 at 37°C). When the cells were 70-90% 
confluent the medium was carefully removed and cells were washed with pre-warmed PBS. 
Cells were detached using pre-warmed Trypsin-EDTA (Invitrogen) at 37°C for 5 minutes. The 
reaction was stopped adding pre-warmed medium (1:1) to the cells and number of viable 
cells was examined by trypan blue staining (Biorad) and counted using Biorad TC10 
automated cell counter. 0.5-1 million cells were transferred into a new culture flask. A549, 
Hela and SF cells were seeded as described in Tab. 2 . 
                                                 Tab. 2: Cell density for different plate types 
Plate type Cell density Medium (ml) 
96-well 10.000 0.1 
24-well 40.000 1 
6-well 500.000 4 
 
For the preparation of liquid nitrogen stocks cells were detached with pre-warmed Trypsin-
EDTA, washed with pre-warmed PBS and resuspended in culture medium containing 10% 
(v/v) DMSO (Carl Roth). They were transferred into cryo vials (VWR) and stored at -80°C for 
2 days. For long-term storage cryo vials were stored in liquid nitrogen. 
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3.1.2 Stimulation with IL-1β 
 
A549 cells or synovial fibroblasts of RA patients were seeded at a density of 4 x 104 cells 
(e.g. 24-well plate) and cultured for 24 h before they were induced with IL-1β for further 24 h. 
A549 cells were stimulated with 5 ng/ml and synovial fibroblasts with 10 ng/ml IL-1β (Sigma 
Aldrich). 
3.2. Transfection of HeLa, A549 and SF cells 
3.2.1 Depletion of CUGBP1, UPF1 and GW182 using RNA interference 
 
CUGBP1, GW182 and UPF1 were transiently depleted using siRNA oligonucleotides. 24 h 
prior to transfection, A549 cells were seeded at a density of 5 x 105 cells/well in a 6-well 
plate. 20 pmol/µl siRNA oligonucleotides were transfected using Lipofectamin2000® 
(Invitrogen) according to manufacturer’s instructions. For UPF1 knockdown, MISSION® 
siRNA SASI_Hs01_00101017-19 (Sigma Aldrich) and for GW182 knockdown, MISSION® 
siRNA SASI_Hs01_00244664 (Sigma Aldrich) were used. For CUGBP1 knockdown a 
previously published siRNA (5´-GCUGUUUAUUGGUAUGAUU-3´) was used for the 
experiments [194]. As control a siRNA against GFP, naturally not expressed, was designed 
(5´-UCUCUCACAACGGGCAUUU-3´). Cells were harvested 24 h and 48 h after transfection. 
The efficiency of UPF1, CUGBP1 and GW182 knockdown was proven by qRT-PCR, 
Western blot analysis and Immunofluorescence staining, respectively. 
3.2.2 Overexpression of miR-574-5p 
 
The miRIDIAN hsa-miR-574-5p mimic (HMI0794, Sigma Aldrich) and negative control 
(HMC0002, Sigma Aldrich) were used for transient overexpression of miR-574-5p. 24 h prior 
to transfection A549 cells were seeded at a density of 5 x 105 per well in a 6-well plate. For 
miR-574-5p overexpression 20 pmol/µl mimics per well were transfected using 
Lipofectamin2000® (Invitrogen) according to the manufacturer´s instructions. The efficiency 
was assessed by qRT-PCR analysis.  
The lentiviral particles Mission® lenti miR-574-5p (HLMIR0794, Sigma Aldrich), respectively 
Mission® lenti control (NCLMIR001, Sigma Aldrich) were used for generating the stable A549 
miR-574-5p overexpression and control cell lines. 24 h prior to transduction, A549 cells were 
seeded at a density of 5 x 105 per well in a 6-well plate. Lenti viral particles were quickly 
thawn and added to A549 cells at an MOI of 0.83 for spinoculation (875 g, 32°C for 60 min). 
The transduced cells were grown for one day before 10 µg/ml puromycin (Sigma Aldrich) 
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was added for four days to select the transduced clones. The transduction efficiency was 
verified by qRT-PCR. The transduction of A549 cells for miR-574-5p overexpression was 
performed by Stefan Stein, Georg-Speyer Haus in Frankfurt. 
3.2.3 Depletion of miR-574-5p by LNAs™ 
 
miR-574-5p was transiently depleted using LNAs™ from Exiqon (miR-574-5p-LNA™ inhibitor 
and a negative control MIMAT0004795). 24 h prior to transfection A549 were seeded at a 
density of 5 x 105 cells per well in a 6-well plate. 40 pmol/µl per well was transfected using 
Lipofectamin2000® (Invitrogen) according to manufacturer’s instructions. The knockdown 
efficiency was assessed by qRT-PCR analysis. 
3.3. DNA methods 
3.3.1 Escherichia coli culture conditions  
 
All media were autoclaved for 20 min at 120°C and 1 bar above atmospheric pressure. Heat-
sensitive materials e.g antibiotics were filtered and then added to the autoclaved medium. In 
disc media 1.5% agar was added before autoclaving. For the cultivation of Escherichia coli 
(E.coli) strains Luria Broth medium (LB) was used. 10 g tryptone (Carl Roth), 10 g NaCl (Carl 
Roth) and 5 g Yeast extract (Carl Roth) were diluted in 1l Milli Q water (MQ). For selections 
100 ug/ml ampicillin (Carl Roth) was added. Cultivation was carried out with shaking at 150 
rpm and 37°C.  
3.3.2 Preparation of chemo competent E.coli cells 
 
100 ml of LB medium was inoculated with 5 ml of an overnight culture and shaked at 150 
rpm at 37°C until OD600 0.4-0.6 was reached. Cells were then incubated for 10 min on 4°C 
and harvested by centrifugation at 4000 rpm for 15 min. Cells were resuspended in sterile 
RF1 solution (50 mM RbCl2, 20 mM MnCl2 x 2 H2O, 15 mM KAc, 5 mM CaCl2, 1.63 M 
glycerine pH 5.8, all chemicals supplied from Carl Roth). Cells were subsequently incubated 
for 1 h at 4°C and harvested by centrifugation for 15 min at 4000 rpm and 4°C. E.coli cells 
were then resuspended in 2 ml RF2 solution (0.7 mM MOPS, 2 mM RbCl2, 15 mM CaCl2 x 2 
H2O, 1.63 M glycerin, pH 6.8, all chemicals supplied from Carl Roth). Cells were incubated 
for 15 min on ice and defined aliquots of the cell suspension were shock-frozen in liquid 
nitrogen and stored at -80°C until usage. 
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3.3.3 Spectrometric quantification of nucleic acids 
 
The determination of the concentration and purity of nucleic acid aqueous solutions (dsDNA, 
ssDNA and RNA) was carried out by UV spectroscopic measurement using the NanoDrop 
ND-1000 spectrophotometer (Thermo Fischer). 
3.3.4 Gel electrophoresis 
 
Nucleic acid electrophoresis was used to separate DNA or RNA fragments by size and 
reactivity. Depending on the desired resolution agarose gels with a concentration of 1-3% 
(w/v) were prepared in TAE buffer (2 M Tris, 1 M Acetic acid, 1 mM EDTA, pH 8.3, all 
chemicals supplied from Carl Roth). The samples were mixed with 6x DNA loading buffer 
(10mM Tris-HCl pH 7.6, 60 mM EDTA, 60% Glycerin, and 0.03% Bromphenol blue, all 
chemicals supplied from Carl Roth) and separated at 8-10 V/cm gel length in 1x TAE buffer. 
As DNA standards Ultra Low Range DNA Ladder II (Peqlab) or 1 kb DNA ladder (Peqlab) 
were used. The gels were stained in ethidium bromide solution (Carl Roth) for 5 min.  
3.3.5 DNA gel extraction 
 
For purification of DNA fragments from agarose gels, the appropriate bands were excised 
and purified by QIAquick™ (Qiagen) gel elution Kit according to manufacturer's instructions.  
3.3.6 Isolation of plasmid DNA 
 
Plasmid DNA was isolated using QIAprep Spin Miniprep Kit (Qiagen) according to 
manufacturer’s instructions. 
3.3.7 Polymerase chain reaction 
 
The amplification of DNA segments was carried out using the polymerase chain reaction 
(PCR). The obtained DNA fragments were used for analysis, cloning or as a template for 
DNA sequencing. The Taq-DNA polymerase (New England Biolabs) or Q5® high-fidelity 
DNA polymerase (New England Biolabs) were used for PCR. The reaction proceeded in a 
thermocycler T100 (Biorad). A typical PCR reaction with 50 µl total volume (Tab. 3) 
contained the following components and has been conducted according to following program 
in Tab. 4. 
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            Tab. 3: Standard PCR mastermix for Taq-polymerase or Q5-DNA polymerase* 
Amount Component 
1 µl Template DNA (chromosomal DNA), Plasmid-DNA ~1-2 ng/ µl 
0.5 µl Oligonucleotide fwd  (100 pMol/ µl) 
0.5 µl Oligonucleotide rev (100 pMol/ µl) 
3 µl 10x dNTP-Mix (2 mM dATP, dGTP, dCTP & dTTP) 
5/10* µl 10x Taq-Pol. buffer  / 5x Q5 reaction buffer* 
0.5 µl DNA-polymerase 
ad 50 µl H2O 
 
 Tab. 4: Standard PCR program for Taq-polymerase or Q5-DNA polymerase* 
Temperature Time Step 
96 °C / 98 °C*  5 min/1 min* Denaturation 
96 °C / 98 °C* 30 sec/10 sec* Denaturation 
52 °C  30 sec Hybridization of oligo- 
nucleotides  
72 °C  60/30* sec pro kb DNA fragment DNA elongation 
72 °C  5 min final DNA elongation 
  4 °C  - cooling 
 
Hybridization temperatures were based on primer length and GC content. The extraction of 
DNA fragments from agarose gels was performed using the Qiaquick™ gel elution kit 
(Qiagen) or Qiaquick™ PCR purification Kit (Qiagen) according to the manufacturer’s 
instructions.  
3.3.8 Fragmentation of DNA using restriction endonucleases 
 
Double-stranded DNA was fragmented with restriction enzymes (New England Biolabs) in 
manufacturer's specified reaction buffer. The amount of enzyme units as well as the duration 
of the restriction was adjusted to the amount of DNA and the characteristics of the 
nucleases. The required amount of restriction enzyme was calculated with Formula 1: 
 
U = Mp	 × 	lr × nplp × nr 
Formula 1: Amount of restriction enzyme. U: enzyme units; mp: mass of dsDNA [ng]; lr: length of reference λ-DNA 
[48502 bp]; np: number of restriction sites within dsDNA; lp: length of dsDNA [bp]; nr: number of restriction sites 
within λ-DNA. 
31-34x 
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3.3.9 Ligation of DNA fragments 
 
Ligation of DNA fragments proceeded after according to Sambrook and Russell established 
method [256]. For ligation vector and insert DNA were used in a molar ratio of 1:3. In                                 
Tab. 5 a standard ligation reaction is listed. 
                                Tab. 5: Standard ligation 
Component Amount 
T4 Ligase buffer (10x)  2 µl 
ATP (1 mM final concentration)  1 µl 
T4 DNA Ligase  2 µl 
MQ ad 20 µl 
 
The T4 DNA Ligase (New England Biolabs) was used for ligation of amplified DNA inserts 
and the digested plasmid. The ligation was performed overnight at 16°C in a total volume of 
20 µl. The ligation performance was controlled by reaction without insert. 
3.3.10 Cloning and plasmid constructs 
 
The pDL Dual Luciferase plasmid, the pCMV-MS and the pCUGBP1 overexpression plasmid 
were kindly provided by Julia Weigand [257]. mPGES-1 3´UTR cDNA was amplified from 
A549 cells using NotI-mPGES-1 3´UTR-forward and HindIII-mPGES-1 3´UTR-reverse 
primers (Tab. 6) and cloned into the pDL Dual Luciferase plasmid via NotI and HindIII 
restriction sites resulting in pDL_mPGES-1 3´UTR plasmid. Deletions of the two GU-rich 
elements were generated by site-directed mutagenesis PCR on mPGES-1 3´UTR plasmid. 
For deletion of the first GRE element the primers ∆GRE1_fw and ∆GRE1_rev (Tab. 6) were 
used resulting in the plasmid pDL_∆GRE1_mPGES-1 3´UTR, followed by DpnI (New 
England Biolabs) digestion. The deletion of the second GU-rich element was generated 
using ∆GRE2_fw and ∆GRE2_rev (Tab. 6) resulting in pDL_∆GRE2_mPGES-1 3´UTR. The 
double deletion mPGES-1 3´UTR-∆GRE1-∆GRE2 was generated by mutagenesis PCR on 
the single mutant pDL_mPGES-1 3´UTR mGRE1 resulting in the plasmid 
pDL_∆GRE1∆GRE2_mPGES-1 3´UTR.  
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Tab. 6: Primers for cloning mPGES-1 3´UTR constructs 
Primer name 5´-3´direction 
mPGES-1 3`UTR-
forward_NotI AAGCGGCCGCCCAGCAGCTGATGCCTCCT 
mPGES-1 3`UTR-
reverse_HindIII AAAGCTTTGCTGGGCCCAGCTGGCA 
∆GRE1_fw TCCCCTTGATGGGGAATCCTTTCTCCTAGACCCGTGACC 
∆GRE1_rev CGGGTCTAGGAGAAAGGATTCCCCATCAAGGGGA 
∆GRE2_fw GCGCGTGTGGGTCTCTGGGCACAGTGGGCCTTTTCTTAGCCCCTTGGATTCCTGC 
∆GRE2_rev GCAGGAATCCAAGGGGCTAAGAAAAGGCCCACTGTGCCCAGAGAC 
 
For the in vitro transcription specific primers for plasmids pHDV_GRE1 and pHDV_GRE2 
(Tab. 7) were used. For pHDV_GRE1 (GRE1_fwd and GRE1_rev) and pHDV_GRE2 
(GRE2_fwd and GRE2_rev) were annealed and cloned via EcoRI and NcoI restriction sites 
into the high-copy-number plasmid pHDV [258]. In this way the HDV ribozyme was added to 
the 3´ end of GRE1 and GRE2 giving homogeneous 3´ends after in vitro transcription. 
 
Tab. 7: Primers for REMSA constructs 
Primer name 5´-3´direction 
GRE1_fw AAAAAAGAATTCTAATACGACTCACTATAGGTGTGTGTGTGCCCGTGT
G 
GRE1_rev TTTTTTCCATGGCCGGCACATACACACACACATACACACACACGGGCA
CACACACACCTATAGT 
GRE2_fw AAAAAAGAATTCTAATACGACTCACTATAGGGTGTGTGTGTGTGTG 
GRE2_rev TTTTACCATGGCCGGCCACACACACACACACACACACACACACACACA
CACACACACACACACCCTATAGTG 
 
3.3.11 Transformation of E.coli 
  
The transformation of the E. coli strains was performed by heat-shock method. The 
chemically competent cells were thawed on ice. In the case of ligation 10 µl mixture was 
transformed. For retransformation 0.5-1 µl plasmid DNA was used. The DNA was added to 
100 µl competent cells and incubated for 30 minutes on ice. This was followed by a heat-
shock (30-45 sec at 42°C). The mixture was briefly cooled on ice, 0.5 ml of LB medium was 
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added and cells were incubated for 1 h at 37°C and subsequently platted on LB plates with 
the appropriate selection marker.  
3.3.12 Sequencing 
 
The sequences of all plasmids were determined based on the method by Sanger reaction. 
The sequencing was performed by SRD (Scientific Research Development, Bad Homburg) 
and Seqlab (Göttingen). 
3.4 RNA methods 
3.4.1 RNA extraction and reverse transcription 
 
Total RNA was extracted with TRIzol Reagent (Invitrogen) and treated with Turbo DNase 
(Ambion) for 5 min according to manufacturer's instructions. 1 µg of DNase-treated RNA was 
used for reverse transcription using High-Capacity RNA-to-cDNA Kit (Applied Biosystems) 
according to manufacturer's instructions. Usually 10 µl 2x RT buffer and 1 µg RNA dissolved 
in 9 µl MQ was mixed with 1 µl RT enzyme. miR-574-5p detection was performed using the 
Qiagen miScript system. 1 µg DNase digested RNA was used for reverse transcription 
according to the manufacturer’s instructions. A standard mix for one reaction was 4 µl 
miScript HiSpec Buffer 5x, 2 µl miScript Nucleic Acid Mix 10x, reverse transcriptase 2 µl, 1 
µg DNase digested RNA and H2O ad 20 µl. 
3.4.2 RT-PCR analysis 
 
Primers mPGES-1 3´UTR forward (CCAGCAGCTGATGCCTCCTTG) and mPGES-1 3´UTR 
reverse (GCCCAGCTGGCAGACACTTCC) were used for specific amplification of mPGES-1 
3´UTR. PCR was carried out using 2.5 U Taq polymerase (New England Biolabs) according 
to the manufacturer's instructions with the addition of 50 µM betaine (Sigma Aldrich). Cycle 
numbers were minimized for each series of experiments in order to keep the PCR reaction in 
the exponential phase and to avoid saturation effects. One tenth of each PCR sample was 
analyzed by gel electrophoresis on a ethidium bromide-stained agarose gel. QIAquick Gel 
Extraction Kit (Qiagen) was used for gel extraction of the RT-PCR products. PCR 
CloningPLUS Kit (Qiagen) was used to clone the isolated PCR fragments according to 
manufacturer's instructions. The selected recombinant plasmids were then sequenced. 
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3.4.3 Real-time quantitative RT-PCR (qRT-PCR) 
 
1 µg of DNase-treated RNA was used for reverse transcription using High-Capacity RNA-to-
cDNA Kit (Applied Biosystems) according to manufacturer's instructions. Real-time PCR was 
performed in Applied Biosystems StepOne Plus™ Real-Time PCR System (Applied 
Biosystem) using Power Syber Green PCR Master Mix (Applied Biosystems). A standard mix 
for one reaction was 10 µl 10x Sybergreen Mastermix, 1 µl cDNA (1:2 diluted), 3.75 µl 
forward Primer (1:50 diluted), 3.75 µl reverse Primer (1:50 diluted), and 1.5 µl H2O. Actin was 
used as endogenous control to normalize variations in cDNA quantities from different 
samples. Each sample was set up in duplicates. Fold inductions were calculated using 
formula 2(-∆∆Ct). The sequences for primer pairs are depicted in Tab. 8. 
                     Tab. 8: Specific primers for qRT-PCR analysis using Sybergreen 
Primer name 5´- 3´direction 
GW182_Fwd AATCTGGTGCAGCAAACTCC 
GW182_Rev AGTGTTTTGTGCAGGGGTTC 
CUGBP1_Fwd AAAGTCCTCCCAGGGATGCA 
CUGBP1_Rev AGCTTCCTGTCTTCCACTGCAT 
3UTRisoform_Fwd GTGCCCGTGTGTGTGTATGTGTGTGTGTGT 
3UTRisoform_Rev CCCAGCTGGCAGACACTTCCATTTAATGACT 
COX-2_Fwd CCGGGTACAATCGCACTTAT 
COX-2_Rev GGCGCTCAGCCATACAG 
mPGES1_Fwd TCCCGGGCTAAGAATGCA 
mPGES1_Rev ATTGGCTGGGCCAGAATTTC 
Actin_Fwd CGGGACCTGACTGACTAC 
Actin_Rev CTTCTCCTTAATGTCACGCACG 
 
qRT-PCR of miR-574-5p expression was performed using the miR-574-5p specific primer 
(MS00043617, Qiagen). RNA U6 primer was used as endogenous control (MS00033740, 
Qiagen). miR-574-5p expression of NSCLC tissue samples were normalized to miRNA 
reverse transcription control using miRTC primer (MS00000001, Qiagen). Real-time PCR 
was performed according to the manufacturer’s instructions. A standard mix for one reaction 
was 12.5 µl QuantiTect Syber Green Mastermix, 2.5 µl miScript Universal primer 10x, 2.5 µl 
U6 or miR-574-5p primer, 1 µl miScript cDNA (1000 ng) and 6.5 µl H2O. Fold inductions were 
calculated using 2(-∆∆Ct) values. 
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3.4.4 In vitro transcription 
 
The GRE1 and GRE2 RNA was in vitro transcribed as described previously [259]. For large 
scale RNA synthesis the RNA was in vitro transcribed using of the linearized (HindIII) 
plasmids pHDV_GRE1 and pHDV_GRE2 (see 3.3.10). Isolated plasmids were linearized 
with HindIII (NEB) and purified by phenol (Carl Roth) treatment. The linear DNA (1-2 mg) 
was mixed with 200 mM Tris-HCl pH 8.0 (Sigma), 20 mM magnesium acetate (Sigma), 50 
mM DTT (Carl Roth), 2 mM spermidine (Carl Roth), 4 mM each NTP (Carl Roth) and 15 ul 
T7 RNA polymerase (NEB). The transcription was incubated for 16 h at 37°C and then 
separated on a 15% denaturing Polyarcylamide (PAA) gel. The product band was excised, 
eluted overnight in 10 ml 300 mM sodium acetate pH 6.5, precipitated in ethanol/acetone 
(1:1) for 1 h  at -20°C and centrifuged for 1 h at 8500 rpm. The RNA containing pellet was 
washed with 70% ethanol and resuspendend in 100 µl autoclaved MQ. 
3.4.5 RNA electrophoretic mobility shift assay (REMSA) 
 
Cytoplasmic extracts were prepared by lysing 4-6 million cells for 10 min on ice in 200 µl 
buffer containing 0.2% Nonidet P-40 (Sigma-Aldrich), 40 mM KCl (Sigma-Aldrich), 10 mM 
HEPES (pH 7.9) (Sigma-Aldrich), 3 mM MgCl2 (Sigma-Aldrich), 1 mM DTT (Sigma-Aldrich), 
5% glycerol (Sigma-Aldrich) and protease inhibitor (Roche). Nuclei were removed by 
centrifugation at 13300 rpm for 2 min and cytoplasmic extracts were immediately frozen on 
dry ice and stored at −80°C. The protein concentration of the extracts was determined by 
Bradford assay (see 3.5.1). GRE1 and GRE2 RNA probes were in vitro transcribed as 
described previously (3.4.4). The miR-574-5p (5´-UGAGUGUGUGUGUGUGAGUGUGU-3´) 
and mGRE1 (5´-GGUCACGGUCACGGUCACGGUCACGGUCACGGUCACGGU-3´) RNA 
probes were commercially synthesized by Sigma Aldrich. RNAs were end labeled with [γ32P] 
ATP (6,000 Ci/mmol, Hartmann) using T4 polynucleotide kinase (Invitrogen) according to the 
manufacturer’s instructions to produce a radioactively labeled probe with a specific activity of 
cpm/µg. EMSA assays were conducted by incubating cytoplasmic extracts with the 32P-
labeled RNA probe at room temperature for 30 min in a buffer containing 0.2% Nonidet P-40, 
40 mM KCl, 10 mM HEPES (pH 7.9), 3 mM MgCl2, 1 mM DTT, and 5% glycerol and 5 mg/ml 
heparin sulfate (Sigma-Aldrich). Each reaction contained 10-70 µg of cytoplasmic protein, 
and 10 fmol of radiolabeled RNA probe in a total volume of 15 µl for 20 min. Recombinant 
CUGBP1 protein was purchased by Abnova (H00010656-P01). Each sample was mixed with 
5 µl 5x native loading buffer (50 %, v/v, glycerol, 0.2 % bromophenol blue, 0.5x TRIS-Borate-
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EDTA buffer, Sigma-Aldrich). The mixtures were separated by electrophoresis under 
nondenaturing conditions on 6% polyacrylamide gels. The gels were analyzed on a Typhoon 
phosphorimager (Amersham Biosciences). 
3.5 Protein methods 
3.5.1 Protein concentration determination 
 
The protein content was determined by Bradford assay (BioRad Laboratories). A standard 
curve was determined with BSA concentrations of 50-500 µg/ml. 10 µl of the different BSA 
concentrations, as well as 10 µl of the cell extract (0.5 µl probe + 9.5 µl MQ), were 
transferred on a 96-well plate and 190 µl of the Bradford reagent was added. The absorption 
at 595 nm was measured at a Tecan Infinte M 200 (Tecan Group). The protein concentration 
was calculated according to the determined standard curve. 
3.5.2 Cell lysis  
 
Cells were lysed in T-PER™ tissue protein extraction reagent (Life technologies) with EDTA-
free protease inhibitor (Roche) for 30 min at 4°C. The protein content of the supernatant was 
determined by Bradford assay (BioRad Laboratories, see 3.6.1). 
3.5.3 SDS-PAGE and Western Blot 
 
60–120 µg protein lysate depending on the approach was separated by Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 12%, transferred to a HyBond ECL 
nitrocellulose membrane (Amersham) and blocked with Odyssey blocking buffer (LI-COR® 
Bioscience) for 1 h at room temperature. The membranes were then incubated over night at 
4°C with primary antibodies that recognize mPGES-1 (Cayman and [260]), GAPDH (2118, 
Cell signaling), CUGBP1 (ab9549, Abcam), phosphorylated CUGBP1 (15903, Abnova), 
Lamin a/c (4777S, Cell signaling) and COX-2 (sc-1745, Santa Cruz). Membranes were 
washed with PBS (Invitrogen) pH 7.4/Tween20 0.1% (v/v) (Carl Roth) and incubated with 
infrared dye conjugated secondary antibodies (IRDye®, LI-COR® Bioscience) for 45 min at 
room temperature. Membranes were washed three times with PBS-Tween buffer. 
Visualization and quantitative analysis was carried out with the Odyssey Infrared Imaging 
System (LI-COR® Biosciences).  
For separating nuclear and cytosolic fractions 0.5-1 million cells were lysed in 75 µl cytosolic 
extraction buffer containing 10 mM HEPES pH 7.9 (Sigma Aldrich), 1,5 mM MgCl2 (Sigma 
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Aldrich), 10 mM KCl (Sigma Aldrich), EDTA-free protease inhibitor (Roche) on ice for 5 min. 
Afterwards samples were centrifuged for 3 min (6500 rpm). The supernatant contained the 
cytosolic fraction. The pellet was further resuspended in nuclear extraction buffer containing 
20 mM HEPES pH 7.9, 1,5 mM MgCl2, 0,42 M NaCl (Sigma Aldrich), 0,2 mM EDTA (Sigma 
Aldrich) 25 % glycerin (Sigma Aldrich) and protease inhibitor EDTA-free (Roche) for 15 min 
at -80°C. Samples were frozen and thawed at 37°C three times. Samples were centrifuged 
for 15 min at 13300 rpm. The supernatant contained the nuclear fraction. 
                                                            Tab. 9: Dilution of antibodies 
Primary antibody Dilution 
Actin 1:1000 
CUGBP1 1:500 
CUGBP1-P 1:250 
GAPDH 1:1000 
mPGES-1 1:250 
Lamin a/c  1:1000 
COX-2  1:200 
 
3.6 Luciferase reporter gene assay 
 
24 h prior to transfection, 4 × 104 HeLa cells per well were seeded in 24-well plates. 100 
ng/well of mPGES-1 3´UTR constructs and 300 ng/well pCUGBP1 [257] or pCMV-MS as 
control, respectively, were used for transfection with Lipofectamin2000® (Invitrogen) 
according to the manufacturer´s instructions. After 48 h, cells were assayed for luciferase 
activity using the Dual-Glo™ Stop and Glow Luciferase Assay System (Promega) with a 
TECAN infinite M200 reader. Renilla luciferase activity was used to normalize the luciferase 
activity to the transfection efficacy. 
3.7 Tetrazolium reduction assay 
 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium (Carl Roth) 
reduction assay was performed to investigate metabolic active and proliferating cells. 24 h 
prior transfection, A549 cells were seeded at a density of 10.000 cells per well in 96-well 
plates. (The mPGES-1 inhibitor CIII was kindly provided by Prof. P.-J Jakobsson). For the 
MTT cell proliferation assay 20 µl of 5 mg/ml MTT (in PBS) was added to the cells in culture 
and incubated for 4 h. The media was removed and 100 µl DMSO (Carl Roth) was added. 
The quantity of formazan was measured by recording changes in absorbance at 570 nm 
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using a plate reading spectrophotometer. As reference the wavelength of 630 nm was used 
to correct nonspecific background values. 
3.8 Immunofluorescence staining of cells 
 
5 × 105 A549 cells were seeded on cover slides 18 x 18 cm in 6-well plates and cultured 
before they were fixed using 500 µl 4% cold Paraformaldehyde (PFA, Carl Roth) for 15 min. 
Twice washed with PBS, followed by 5 min permeabilization with 500 µl 0.5% Triton X-100 
(Sigma Aldrich). The cells were blocked with 1 ml 2% BSA in PBS (Sigma Aldrich) for 1 h. 
Primary antibodies GW182 (ab66009), CUGBP1 (ab9549), and DCP1a (ab70522), all 
purchased from Abcam, were diluted in blocking buffer and incubated with cells overnight at 
4°C (Tab. 10). Cells were washed twice with PBS and incubated with secondary antibody 
(1:1000) goat anti-mouse IgG (Alexa Fluor® 594, ab150116) or goat anti-rabbit IgG (Alexa 
Fluor® 488, ab150077), respectively, from Abcam for 2 h at room temperature. Cells were 
stained with 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI, Sigma Aldrich) for 2 min. 
Images were processed with 20 x magnitude using Axio Observer microscope (Zeiss, Jena, 
Germany) with LSM 510 Meta (Zeiss) image-processing software. 
                                                            Tab. 10: Dilutions of antibodies 
Primary antibody Dilution 
GW182 1:100 
CUGBP1  1:500 
DCP1a 1:1000 
3.9 Prostaglandin E2 levels in supernatants 
 
Prostanoids from cell culture supernatants were extracted using a 30 mg 1cc HLB single 
extraction column (Waters Corporation, Milford, MA, USA). 1 ml methanol was used to pre-
condition the column followed by a wash with 1 ml deionized water acidified with 0.05% 
formic acid. Sample was loaded to the column and was subsequently washed with 1 ml 
deionized water containing 5% methanol acidified with 0.05% formic acid. Sample was eluted 
into 1 ml methanol and evaporated under vacuum. For LC-MS/MS analysis samples were 
resolved in 50 µl deioinized water containing 7% acetonitrile (Merck Millipore) prior to 
analysis by Waters 2795 HPLC (Waters Corporation, MA, USA) coupled to a triple 
quadrupole mass spectrometer (Acquity TQ Detector, Water Corporation). Injection of 40 µl 
aliquots was made to a Synergi Hydro-RP column (100 mm x 2 mm i.d, 100 Å pore size and 
2.5 µm particle size, Phenomenex, CA) with a 45 min stepwise linear gradient. As mobile 
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phase A, deionized water was used; acetonitrile acidified with 0.05% formic acid was used as 
mobile phase B. The first step with the duration of 9 min was followed by mobile phase B 
increased from 10% to 25%, then to 45% during 22 min in step two and moreover to 70% 
during 5 min in step three. 90% mobile phase B was applied as washing step and then re-
equilibrated at 10 % mobile phase. Multiple reaction monitoring (MRM) mode was used for 
detection of analyses and quantified using internal standard calibration for PGE2, PGD2, 
PGF2α, TXB2, 6-keto-PGF1α, 13,14-dihydro-15-keto-PGE2 and 15-deoxy-∆12,14 PGJ2. 
Prostaglandin levels in supernatants were kindly analyzed by J. Raouf and H. Idborg, 
Karolinska Institut, Stockholm. Supernatants of the stable integrated A549 cell lines were 
kindly analyzed by Prof. P. Patrignanis Laboratory, University of Chieti, Italy. 
3.10 Animal experiments 
 
CD-1® Nude mice were purchased from (Charles River, Milan, Italy). The animals were 
housed in cages up to five mice each and acclimated for one week under conditions of 
controlled temperature (20±2°C), humidity (55±10%), and lighting (7:00 a.m. to 7:00 p.m.). 
For all experiments, mice were housed under specific pathogen-free conditions and allowed 
free access to food and water. Age-matched female (6-week-old to 8-week-old) were used 
for all experiments. A549 control cells or A549 miR-574-5p oe cells were resuspended in 
PBS (5x106/100µl) and then subcutaneously injected into both dorsal flanks of mice to 
establish a model of tumour-bearing mice. For the in vivo studies, the mPGES-1 inhibitor 
(CIII, 28575) was dissolved in 1% Tween 80 (Sigma-Aldrich) and 0.5% 
carboxymethylcellulose (Sigma-Aldrich) in 0.9% NaCl solution (vehicle) and administered 
every day (50 mg/kg, i.p.), once a day from tumour cell implantation until sacrifice (day 27, 
i.e. for 4 weeks). Control mice received A549 control cells (n=8) or A549 miR-574-5p oe cells 
(n=8) and were treated with vehicle, every day, once a day by i.p. injection from tumour cell 
implantation until sacrifice. A group of mice (n=6) received A549 control cells or A549 miR-
574-5p oe cells (n=6) and were treated with CIII (50 mg/kg) every day, once a day by i.p. 
injection from tumour cell implantation until sacrifice. Tumour growth was monitored three 
times a week from tumour cell implantation until sacrifice by measuring its diameter with a 
digital calliper. Tumour volume (TV) was calculated by [TV(cm3) = length[D(cm)]×width 
[d(cm)2]×0.44]. Body weight was monitored three times a week until sacrifice and tumour 
weight of dissected tumours was assessed at the sacrifice. Mice were sacrificed after 4 
weeks from tumour cell implantation, 30 min after the last treatment. The experiments were 
performed in the lab of Prof. P. Patrignani University of Chieti, Italy. 
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3.11 Statistics 
 
Results are given as mean + SEM of three independent experiments. Statistical analysis was 
carried out by Student's paired or unpaired t-test (two-tailed), respectively, for the time 
course experiments with 2-way ANOVA (Bonferroni post test) using GraphPad Prism 5.0. 
Differences were considered as significant for p<0.05 (indicated as * for p<0.05, ** for p<0.01 
and ***for p<0.001). 
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4 Results 
4.1 A novel mPGES-1 3´UTR splice variant regulated by CUGBP1 
4.1.1 Identification and characterization of a novel mPGES-1 3´UTR variant 
 
A pilot study of the P.-J. Jakobsson and D. Steinhilber groups revealed the existence of 
different splice variants of mPGES-1 mRNA in different cell lines analyzed by RT-PCR and 
sequence analysis. One of these splice variant was further investigated in synovial fibroblast 
from rheumatoid arthritis (RA) patients, adenocarcinoma cell line A549 and cervix carcinoma 
cell line HeLa, since they are well-established systems for characterizing mPGES-1 
expression [70]. To investigate the existence of one of the mPGES-1 splice variants RT-PCR 
analysis was performed in these cell lines with specific primers (mPGES-1 3´UTR forward 
and reverse, chapter 3.4.2) covering the complete 3´UTR (Data from Meike Saul). The 
analysis revealed the presence of a novel short 3´UTR variant (Fig. 13 A). Sequence 
analysis demonstrated that mPGES-1 3´UTR isoform was generated by splicing out an 
intron, which removes the middle part of the 3´UTR (Fig. 13 B).  
 
Fig. 13: Identification and characterization of a novel mPGES-1 3´UTR isoform. (A) RT-PCR products 
obtained with a primer pair (see chapter 3.4.2) covering complete mPGES-1 3´UTR in synovial fibroblasts of RA 
patients, A549 and HeLa cells separated on a 1% agarose gel. The existence of the PCR products were 
confirmed by at least one sequenced recombinant clone. (B) Schematic representation of the identified mPGES-1 
3´UTR isoform. GU-rich elements (GREs) are indicated by black boxes. 
4.1.2 CUGBP1 binds to GU-rich elements within mPGES-1 3´UTR  
 
Interestingly, both intron boundaries are flanked by GU-rich elements (GREs) [254], GRE1 
position chr9:129739418-129739456 39bp and GRE2 chr9:129738411-129738458 46bp, 
which may represent binding sites for the RNA-binding protein CUGBP1 [195]. It has been 
described for e.g. JunD and NDUFS2 that GU-repeat sequences are binding sites for 
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CUGBP1 [195,203]. To prove the binding affinity of CUGBP1 to GRE1 and GRE2 of 
mPGES-1 3´UTR, RNA EMSAs (REMSAs) were performed with radiolabeled RNA probes of 
GRE1 and GRE2. Therefore various cytosolic protein lysates of A549 cells with or without 
CUGBP1 overexpression (CUGBP1 oe) were prepared. The overexpression of CUGBP1 
protein was confirmed by Western blot analysis and revealed a 3.5 fold induction (Fig. 14). 
                                     
Fig. 14: Quantification of CUGBP1 overexpression in A549 cells via Western Blot analysis. A549 cells were 
transfected with 500 ng CUGBP1 overexpression plasmid or pCMV-MS control plasmid, respectively and 
collected 48 h after transfection. GAPDH was used as endogenous loading control. A representative Western blot 
of three idependent experiments is shown. The relative changes to control samples were given as mean + SEM of 
three independent experiments; t-test, p* < 0.05. 
Cytosolic extracts were incubated with radiolabeled GRE1 and GRE2 RNA probes. The 
shorter element (GRE1) was mutated to mGRE and used as negative control. The 
sequences are depicted in Fig. 15 A. Protein-RNA complexes were separated by a 6% native 
polyacrylamide gel. For GRE1 and GRE2, a shift could be observed using 10 µg cytosolic 
extract. For the mutated RNA probe mGRE no shift was detectable (Fig. 15 B). Additionally, 
REMSAs were performed using GRE-containing RNA probes and cytoplasmic lysates 
prepared from A549 cells, which were previously transfected with a CUGBP1 overexpression 
plasmid. As shown in Fig. 15 B, a protein-RNA complex was detected in response to 
CUGBP1 oe. The binding of GRE1 and GRE2 RNA probes was attributed to CUGBP1 since 
CUGBP1 oe led to a stronger RNA shift compared to control cells (Fig. 15 B). The shifts were 
abolished by addition excess amount of non-labeled RNA probes or using mGRE RNA probe 
(Fig. 15 C).  
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Fig. 15: CUGBP1 binds selectively to GU-rich elements of mPGES-1 3´UTR. (A) Sequences of GRE1, GRE2 
and mutated mGRE. (B) REMSAs of radiolabeled GRE1, GRE2 and mGRE with 10 µg cytosolic protein. (C) 
REMSAs of radiolabeled GRE1, GRE2 and mGRE with 50 µg cytosolic protein. Unlabeled RNA was added for 
competitive shift of GRE1 and GRE2. RNA-protein complexes were separated by electrophoresis under non-
denaturing conditions (6% PAA-Gel). Gels were analyzed on a phosphorimager. A representative REMSA of 
three idependent experiments is shown. 
4.1.3 CUGBP1 mediates splicing and mRNA degradation of mPGES-1 3´UTR  
 
Currently, nothing is known whether CUGBP1 regulates mPGES-1 expression, but it has 
been shown that CUGBP1 associates with mPGES-1 mRNA in mouse myoblast cells [261]. 
It has been described that binding of CUGBP1 to GREs leads to alternative splicing in the 
nucleus [180,194,262]. Therefore, the next step was to investigate whether splicing of 
mPGES-1 3´UTR is regulated by CUGBP1. Hence, reporter gene assays with different 
mPGES-1 3´UTR constructs in response to CUGBP1 oe were performed in HeLa cells. HeLa 
cells were transfected with CUGBP1 oe plasmid (see 3.3.10) or pCMV-MS control plasmid, 
respectively, to quantify CUGBP1 oe in HeLa cells. CUGBP1 protein expression was 
increased to 8.5-fold in HeLa cells after 48 h compared to control level (Fig. 16 A). Then 
HeLa cells were cotransfected with the wildtype mPGES-1 3´UTR reporter plasmid and 
CUGBP1 oe plasmid in increasing ratios to identify optimal working concentration for the 
luciferase reporter gene assay. The reporter gene assay demonstrated a significant 
reduction of luciferase activity of mPGES-1 3´UTR by CUGBP1 oe compared to control for 
each ratio (Fig. 16 B), assuming that there might be an event of splicing. The optimal ratio 
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1:3 (mPGES-1 3´UTR construct: CUGBP1 oe construct) was used for further experiments as 
luciferase activity was significantly reduced to ~70%. 
 
Fig. 16: Quantification of CUGBP1 overexpression and mPGES-1 3´UTR reporter gene assay in HeLa 
cells. (A) For CUGBP1 oe HeLa cells were transfected with 500 ng CUGBP1 oe plasmid or pCMV-MS control 
plasmid, respectively and collected 48 h after transfection. GAPDH was used as loading control. A representative 
Western blot of three independent experiments is shown. The relative changes to control samples were given as 
mean + SEM of three independent experiments; t-test, p* < 0.05; **p < 0.01. (B) CUGBP1 oe regulates mPGES-1 
3´UTR gene expression dose-dependently. Reporter gene assay of mPGES-1 3´UTR construct (100 ng) in HeLa 
cells subjected to CUGBP1 oe in different concentrations. The relative changes to control samples were given as 
mean + SEM of three independent experiments; t-test, p* < 0.05; **p < 0.01, ***for p<0.001. 
It was then interesting to elucidate if GU-rich elements have an influence on splicing 
mPGES-1 3´UTR, therefore HeLa cells were cotransfected with different mPGES-1 3´UTR 
reporter gene constructs and the CUGBP1 oe plasmid. In addition to the wildtype mPGES-1 
3´UTR containing plasmid, three additional plasmids were designed with sequential deletion 
of the GRE elements and the double deletion. The decreased luciferase activity of mPGES-1 
3´UTR in response to CUGBP1 oe was abolished by the sequential and the double deletion 
of GREs (Fig. 17 A). The luciferase activity was restored up to control level. RT-PCR 
analysis primer pairs covering mPGES-1 3´UTR (see chapter 3.4.2) confirmed the reporter 
gene assay results, as no mPGES-1 3´UTR isoform PCR splice product could be detected 
by the sequential or double deletion of GREs (Fig. 17 B). These data suggest mPGES-1 
3´UTR splicing was mediated by CUGBP1 whereby both GREs are essential for splicing.  
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Fig. 17: CUGBP1 is responsible for mPGES-1 3´UTR splicing. (A) Reporter gene assay of mPGES-1 3´UTR 
constructs in HeLa cells subjected to CUGBP1 oe (ratio 100:300 ng). The black boxes indicate GREs within 
mPGES-1 3´UTR, whereas the grey boxes indicate deleted GREs. The relative changes were given as mean + 
SEM of minimum three independent experiments; t-test, p* < 0.05; **p < 0.01, ***for p <0.001. (B) RT-PCR 
analysis using primer pair (see chapter 3.4.2) covering mPGES-1 3´UTR in HeLa cells, previously transfected 
with mPGES-1 3´UTR constructs with CUGBP1 oe or pCMV-MS control, respectively. RT-PCR products were 
separated on a 1% agarose gel. A representative gel of three independent experiments is shown. 
The reporter gene assay in HeLa cells demonstrated a decreased luciferase activity for 
mPGES-1 3´UTR in response to CUGBP1 oe suggesting that mRNA stability might be 
affected by the GREs and CUGBP1 binding. Therefore, mRNA stability of mature mPGES-1 
and splice variant mRNA was addressed by comparing mRNA levels in A549 cells treated 
with actinomycin D. Actinomycin D is a peptide antibiotic that inhibits RNA synthesis. As 
shown in Fig. 18 A exposure to actinomycin D treatment resulted in a substantial decrease in 
the amount of mPGES-1 isoform mRNA in contrast to mature mPGES-1 mRNA. Previously, 
Rattenbacher et al. demonstrated that GU-rich containing mRNA transcripts are rapidly 
degraded by CUGBP1-dependent recruiting of PARN deadenylases [195]. Alternatively, the 
3´UTR isoform is also an NMD target by placing the natural stop codon in front of an EJC 
rendering it into a PTC [263]. To determine which mechanism is responsible for mRNA 
degradation of 3´UTR isoform UPF1 knockdown experiments were performed in A549 cells. 
The siRNA-mediated knockdown of the crucial NMD factor UPF1 led to a 73% reduction of 
UPF1 protein using siRNA C (Fig. 18 B). No significant changes in mRNA expression of 
mPGES-1 and the 3´UTR variant were observed with the inhibition of NMD factor UPF1 (Fig. 
18 C), assuming that mRNA decay of mPGES-1 3´UTR is UPF1 independent and mRNA 
degradation of mPGES-1 splice variant is mediated by CUGBP1. Taken together these data 
indicate that CUGBP1 negatively influences mPGES-1 3´UTR isoform mRNA stability via 
binding to GU-rich elements, however the mature mPGES-1 mRNA transcript is not affected. 
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Fig. 18: mRNA decay of mPGES-1 3´UTR is UPF1 independent. (A) Remaining mPGES-1 3´UTR isoform and 
mPGES-1 mRNA expression 24 h after actinomycin D treatment (2 µg/ml) at indicated time points. Relative 
changes were given as mean + SEM of three independent experiments; two way ANOVA, Bonferroni post test, 
*p < 0.05, **p < 0.01, ***for p<0.001. Actin was used as control. (B) Quantification of UPF1 knockdown in A549 
cells via Western Blot analysis. A549 cells were transfected with 20 pmol/ul siRNA or control siRNA, respectively 
and collected 24 h after transfection. GAPDH was used as loading control. A representative Western blot of three 
idependent experiments is shown. The relative changes were given as mean + SEM of minimum three 
independent experiments; t-test, p* < 0.05; **p < 0.01, ***for p<0.001. (C) Effect of NMD inhibition by UPF1 
knockdown on mPGES-1 3´UTR isoform and mPGES-1 mRNA expression 24 h after transfection. Actin was used 
as control. Relative changes are given as mean + SEM of three independent experiments; t-test. 
4.1.4 Depletion of CUGBP1 stabilizes 3´UTR variant and mPGES-1 protein expression 
 
CUGBP1 is a multifunctional protein whereupon its functions are determined by its cellular 
localization and phosphorylation status. In the cytosol, it regulates translation efficiency and 
mRNA stability [195] whereas nuclear located CUGBP1 is involved in the regulation of 
alternative splicing [194]. Here in this study it was demonstrated that CUGBP1 mediates 
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mPGES-1 3´UTR splicing and degradation of 3´UTR isoform (Fig. 17). Mature mPGES-1 
mRNA was not affected, although it contains the two GRE elements in its 3´UTR, suggesting 
that cytosolic CUGBP1 might regulate translation. Treatment with cytokines e.g. IL-1β can 
highly induce mPGES-1 expression [11]. To investigate mPGES-1 mRNA and protein 
expression pattern regulated by CUGBP1, the protein was depleted using RNAi. As shown in 
Fig. 19 the siRNA-mediated knockdown (∆CUGBP1) lead to a ~80% reduction of CUGBP1 
protein expression in A549 cells using Western blot analysis. 
                                      
Fig. 19: Quantification of CUGBP1 knockdown in A549 cells via Western Blot analysis. A549 cells were 
transfected with 20 pmol/µl siRNA or a control siRNA, respectively and collected 24 h after transfection. GAPDH 
was used as loading control. A representative Western blot of three idependent experiments is shown. The 
relative changes were given as mean + SEM of minimum three independent experiments; t-test, p* < 0.05; 
**p < 0.01. 
Time course experiments in A549 cells were performed to address the effect of CUGBP1 on 
mPGES-1 mRNA and protein expression. The mPGES-1 expression was induced by 
stimulating the cells with 5 ng/ml IL-1β for 24 h, afterwards the medium was changed and IL-
1β depleted. The cells were then cultivated for further 24 h to find the natural downregulation 
mechanisms. At defined time points, samples were collected for mRNA, protein and PGE2 
analysis. The time course experiments revealed that the mRNA of mPGES-1 3´UTR isoform 
was 8.7 fold induced in response to ∆CUGBP1 compared to the control after IL-1β 
stimulation (Fig. 20 A). The 3´UTR isoform mRNA expression was increased to 7.6 fold until 
9 h after medium change, which indicates that CUGBP1 acts as mRNA decay factor for the 
mPGES-1 3´UTR isoform [177,264]. The mature mPGES-1 mRNA in contrast was less 
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affected by ∆CUGBP1 (Fig. 20 B), even after medium change without cytokine stimulus. A 
slight increase in mPGES-1 mRNA expression by ∆CUGBP1 compared to control was 
observed. A similar expression pattern was determined for mPGES-1 protein expression, 
differing only in a stronger upregulation in response to ∆CUGBP1 (Fig. 20 C). After IL-1β 
stimulation mPGES-1 protein expression increased up to 5.8 fold induction (∆CUGBP1) 
compared to 2.8 fold for the control. Depletion of CUGBP1 led to 6.9 fold induction in 
contrast to 4.0 fold for mPGES-1 protein 24 h after cultivation without stimulus.  
Also PGE2 levels in supernatants were measured to investigate changes in product formation 
downstream of mPGES-1. Interestingly, the enzymatic product of mPGES-1 was significantly 
upregulated to ~50 fold in response to ∆CUGBP1 after IL-1β induction, but rapidly decreased 
after IL-1β depletion in contrast to mPGES-1 mRNA and protein level (Fig. 20 D). It has been 
demonstrated that PGE2 regulation by mPGES-1 sometimes acts in concert with COX-2 [61]. 
Therefore, the COX-2 mRNA and protein level was monitored during this time course to 
investigate decreasing PGE2 level and whether CUGBP1 had also an influence on COX-2 
expression. qRT-PCR and Western blot analysis of the time course experiment revealed that 
mRNA (Fig. 20 E) as well as protein (Fig. 20 F) expression of COX-2 was markedly induced 
by IL1-β stimulation after 24 h, but after IL-1β depletion a strong downregulation of COX-2 
expression was observed. ∆CUGBP1 had no influence on COX-2 expression. These data 
suggest that CUGBP1 acts as decay factor for mPGES-1 3´UTR mRNA regulating mPGES-1 
protein expression independent from COX-2. 
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Fig. 20: Effect of CUGBP1 knockdown on mPGES-1 and COX-2 expression. A549 cells were transfected with 
20 pmol/µl siRNA or control siRNA, respectively and incubated with 5 ng/ml IL-1β for 24 h. Afterwards cell culture 
medium was replaced by cell culture medium without IL-1β. The cells were cultured for further 24 h.Samples were 
collected at different time points. qRT-PCR analysis of (A) mPGES-1 and (B) mPGES-1 3´UTR isoform mRNA 
expression. Actin was used as control. (C) Western blot analysis of mPGES-1 expression (D) LC-MS/MS analysis 
of PGE2 level. (E) qRT-PCR analysis of COX-2 mRNA expression. Actin was used as control. (F) Western blot 
analysis of COX-2 protein expression level. For Western blot analysis GAPDH was used as loading control. A 
representative blot of three independent experiments is shown. The relative changes were given as mean + SEM 
of three independent experiments, two way ANOVA, Bonferroni post test, *p < 0.05, **p < 0.01, ***for p<0.001. 
Kojima et al., demonstrated that mPGES-1 was induced in cultured synovial fibroblasts 
obtained from RA patients, upon stimulation by pro-inflammatory cytokines such as IL-1β and 
TNF-α [38]. It was interesting to elucidate if CUGBP1 depletion showed similar effects on SF 
cells of RA patients. To address these issues SFs of five patients (SF0246, SF0252, SFHW, 
SF5, SF2) were cultured for 24 h and transfected with CUGBP1 siRNA and a control siRNA, 
respectively. During cultivation SF5 showed an abnormal phenotype and was not used for 
further analysis. The knockdown of CUGBP1 in SF2 did not show a reduction of CUGBP1 
mRNA, maybe due to low transfection efficiency. The siRNA-mediated knockdown of 
CUGBP1 of the remaining SF cells lead to ~59% reduction of CUGBP1 mRNA (Fig. 21 A). 
According to the results in A549 cells there were no significant changes in IL-1β induced 
mPGES-1 mRNA expression levels (10 ng/ml) in response to ∆CUGBP1 (Fig. 21 C). 
Interestingly, IL-1β induced induction of mPGES-1 3´UTR isoform demonstrated a slightly 
increase in response to ∆CUGBP1 (Fig. 21 C). Preliminary data in SF0246 showed that 
CUGBP1 protein was slightly reduced after IL-1β stimulation, whereas mPGES-1 protein was 
slightly increased after stimulation (Fig. 21 B). These data stand in line with the A549 results 
and suggest that CUGBP1 is responsible for GU-mediated mRNA decay and degradation of 
the mPGES-1 3´UTR isoform in SF cells. Additionally, the data indicates that CUGBP1 might 
repress mPGES-1 protein translation. 
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Fig. 21: Effect of CUGBP1 knockdown on induced mPGES-1 and mPGES-1 3´UTR expression in SF cells 
of RA patients. SF-0246, SF-0252 and SF-HW were transfected with 20 pmol/µl siRNA or control siRNA, 
respectively. 24 h after transfection cells were incubated with 10 ng/ml IL-1β for further 24 h. (A) qRT-PCR 
analysis of CUGBP1 mRNA expression. Actin was used as control. (B) Western blot analysis of CUGBP1 and 
mPGES-1 protein expression in SF-0246 with depleted CUGBP1 levels. SF-0246 was transfected with 20 pmol/µl 
siRNA, or a control siRNA respectively. 24 h after transfection cells were incubated with 10 ng/ml IL-1β for further 
24 h. GAPDH was used as loading control. (C) qRT-PCR analysis mPGES-1 and mPGES-1 3´UTR isoform 
mRNA expression in SF-0246, SF-0252 and SF-HW in response to ∆CUGBP1. Actin was used as control. The 
relative changes were given as mean + SEM of three independent experiments; t-test, p* < 0.05; **p < 0.01. 
4.1.5 mPGES-1 protein translation is repressed by CUGBP1 overexpression  
 
A549 cells were transfected with the CUGBP1 overexpression plasmid (500 ng) for 48 h to 
investigate the effects of CUGBP1 overexpression on mPGES-1 expression pattern. The 
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time course experiment 48 h after transfection (see Chapter 4.1.4) could not be analyzed 
because long-term overexpression of CUGBP1 led to a decreased cell viability in A549 cells 
(Fig. 22). Trypan blue, a diazo dye, was used to selectively stain dead cells [265]. The 
measurement of cell viability demonstrated that CUGBP1 overexpressing A549 cells showed 
less viable cells during this time course compared to the control. Therefore samples for qRT-
PCR and Western blot analysis were collected 48 h after transfection and an additional 
incubation with IL-1β for 24 h.  
 
Fig. 22: Cell viability of A549 cells analyzed by Trypan blue measurement. A549 cells were transfected with 
500 ng CUGBP1 oe plasmid or pCMV-MS control plasmid, respectively and collected at different time points. 48 h 
after transfection the cells were induced with 5 ng/ml IL-1β for further 24 h. Samples were collected at different 
time points. The relative changes were given as mean + SEM of minimum three independent experiments; two 
way ANOVA, Bonferroni post test, *p < 0.05, **p < 0.01, ***for p<0.001. 
qRT-PCR analysis demonstrated that CUGBP1 oe did not alter mPGES-1 mRNA expression 
levels with and without IL-1 β stimulation (Fig. 23 A). However, IL-1β mediated induction of 
mPGES-1 3´UTR isoform was slightly decreased compared to control (Fig. 23 A) but not 
significantly reduced. In contrast to this, it could be shown that IL-1β mediated induction of 
mPGES-1 protein was significantly repressed by CUGBP1 oe (Fig. 23 B). These experiments 
indicate that CUGBP1 functions as destabilizing factor for mPGES-1 3´UTR isoform and as a 
translational repressor for mPGES-1 protein expression. 
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Fig. 23: Effect of CUGBP1 oe on IL-1β mediated induction of mPGES-1 expression. A549 cells were 
transfected with 500 ng CUGBP1 oe plasmid or pCMV-MS control, respectively and induced 48 h after 
transfection with 5 ng/ml IL-1β for further 24 h. (A) qRT-PCR analysis of mPGES-1 and mPGES-1 3´UTR isoform 
mRNA expression in response to CUGBP1 oe. Actin was used as control. (B) Western blot analysis of mPGES-1 
protein expression in response to CUGBP1 oe. GAPDH was used as loading control. A representative Western 
blot of three idependent experiments is shown. The relative changes were given as mean + SEM of minimum 
three independent experiments; t-test, p* < 0.05. 
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4.1.6 GW182 acts in concert with CUGBP1 and is crucial for mPGES-1 protein 
expression 
 
Studies in mammalian cells have revealed that mRNA decay intermediates accumulate at P-
bodies (PBs) when normal decay is blocked suggesting that PBs are sites of decapping and 
5´-3´degradation [266,267,268]. Kedersha et al. showed that mRNA-decapping enzyme 1a 
(DCP1a) [269] and glycine-tryptophan protein (GW182) [270] are components of PBs 
[269,270]. Moreover, Yu et al. showed that translation repression of target mRNA was due to 
colocalization of CUGBP1 and tagged mRNA in PBs [151,271]. To verify the hypothesis that 
CUGBP1 might repress mPGES-1 translation by recruiting mPGES-1 mRNA to PBs, the 
distribution of CUGBP1 and the PB component DCP1a was examined by 
immunofluorescence stainings. Immunofluorescence analysis demonstrated extensive 
colocalization of CUGBP1 and DCP1a (Fig. 24 A). The stainings showed that CUGBP1 was 
rather located in the nucleus than in the cytosol. It has been shown that depletion of the PB 
marker GW182 can disrupt PBs formation and stability. Therefore, GW182 (∆GW182) was 
depleted to determine whether GW182 is linked to translation repression mediated by PBs. 
Immunoflourescence stainings showed a slight decrease of GW182 expression for ∆GW182 
cells after 24 h compared to the control cells (Fig. 24 B). This was also confirmed by qRT-
PCR. The knockdown of GW182 led to a ~55% reduction of GW182 mRNA expression (Fig. 
24 C). It has been demonstrated that GW182 is partly involved in miRNA biosynthesis and 
knockdown can influence miRNA maturation for some miRNAs. As an example, for miR-575-
5p no significant changes could be detected in response to ∆GW182 (Fig. 24 D). As 
expected the mature mPGES-1 mRNA was not affected by ∆GW182 (Fig. 24 E), whereas 
the protein expression was significantly induced in A549 cells with depleted GW182 (Fig. 24 
F), suggesting that GW182 and PB formation is crucial for mPGES-1 protein translation. 
These data indicate the important role of CUGBP1 as translational repressor for mPGES-1 
expression in combination with PB formation mediated by GW182. However, it remains 
unclear how exactly mPGES-1 protein expression is increased by ∆CUGBP1, whether only 
due to mRNA turnover or due to PB formation or a combination of both. 
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Fig. 24: CUGBP1 colocalizes with the PB marker DCP1a and PB formation is crucial for mPGES-1 protein 
translation. (A) Fluorescence analysis of CUGBP1 colocalization with PB protein DCP1a. Alexa Fluor 594® was 
detecting CUGBP1, Alexa Fluor® 488 detecting DCP1a and DAPI detecting nuclei. Scale bar represents 100 µM. 
(B) Fluorescence analysis of GW182 knockdown in A549 cells 24 h after transfection (20 pmol/µl). Alexa Fluor® 
594 was detecting GW182 and DAPI detecting nuclei. Scale bar represents 100 µM. (C) qRT-PCR analysis of 
siRNA-mediated knockdown of GW182 in A549 cells 24 h after transfection. Actin was used as control. (D) miR-
574-5p mRNA expression during ∆GW182 24 h after transfection. U6 was used as endogenous control. (E) qRT-
PCR analysis of mPGES-1 mRNA expression level during GW182 knockdown 24 h after transfection. Actin was 
used as control. (F) Western Blot analysis of mPGES-1 protein expression. GAPDH was used as loading control. 
A representative Western blot of three independent experiments is shown. The relative changes were given as 
mean + SEM of minimum three independent experiments; t-test, p* < 0.05; **p < 0.01. 
4.1.7 CUGBP1 overexpression inhibits the proliferation of A549 cells 
 
It has been demonstrated that proliferation in Lewis lung carcinoma cells was reduced by 
siRNA-mediated knockdown of mPGES-1, indicating the critical role of mPGES-1 in cancer 
progression and tumour growth [33]. Decreased cell viability was observed in response to 
CUGBP1 oe in A549 cells analyzed by Trypan blue measurement (Fig. 22). To investigate 
the influence of CUGBP1 on A549 cell proliferation MTT cell proliferation assays were 
performed. First the influence of IL-1β stimulation on cell proliferation was analyzed. 
Therefore, A549 cells were seeded and stimulated with and without IL-1β for 24 h (Fig. 25 A). 
The induction with IL-1β did not significantly change the cell proliferation after 24 h compared 
to the unstimulated control cells. Interestingly, IL-1β induced cell proliferation was 
significantly increased in response to ∆CUGBP1, whereas CUGBP1 oe significantly 
decreased A549 cell proliferation (Fig. 25 B). 
 
Fig. 25: Effect of CUGBP1 overexpression and knockdown on IL-1β induced cell proliferation. MTT cell 
proliferation assay was performed in A549 cells (A) induced with (5 ng/ml) and without IL-1β for 24 h, (B) 
∆CUGBP1 and CUGBP1 oe. A549 cells were transfected with 500 ng CUGBP1 plasmid or pCMV-MS control, 
respectively for CUGBP1 oe or 20 pmol/µl siRNA for ∆CUGBP1. The cells were induced with IL-1β for 24 h after 
24 h transfection for ∆CUGBP1 or 48 h for CUGBP1 oe. The relative changes were given as mean + SEM of 
three independent experiments; t-test, p* < 0.05. 
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The MTT cell proliferation analysis suggests that CUGBP1 negatively influence cell 
proliferation. 
4.1.8 Expression pattern and localization of CUGBP1 in A549 and SF cells 
 
The function of CUGBP1 is regulated by its cellular localization and phosphorylation status 
[203]. In Fig. 24 A, it was shown that CUGBP1 is located in the nucleus and the cytosol. It 
was observed that CUGBP1 protein is higher expressed in the nucleus than in the cytosol. 
To investigate whether changes in localization, expression level or phosphorylation status of 
CUGBP1 influenced mPGES-1 expression, CUGBP1 mRNA and protein level was observed 
during the defined time course. No significant changes could be determined neither in the 
mRNA expression nor in the protein expression level of CUGBP1 (Fig. 26 A), CUGBP1 was 
constitutively expressed on mRNA and protein level even after IL-1β depletion.  
 
Fig. 26: Expression levels and localization of CUGBP1 during time course experiment. A549 cells were 
induced with 5 ng/ml IL-1β for 24 h. Afterwards cell culture medium was replaced by medium without IL-1β and 
the cells were cultured for further 24 h. Samples were collected at different time points. (A) qRT-PCR and 
Western blot analysis were performed to analyze the CUGBP1 expression profile. Actin was used as control for 
qRT-PCR and GAPDH was used as control for Western blot analysis. Two way ANOVA, Bonferroni post test. (B) 
Western blot analysis of cellular localization of CUGBP1 during time course experiment in the cytosolic fraction 
and the nuclear fraction. Lamin A/C was used a nuclear loading control. GAPDH is located in the nucleus and the 
cytosol. (C) Western Blot analysis of phosphorylation of CUGBP1 (CUGBP1-p) during time course experiment. 
Red bands represent the fluorescense at 680 nm and green bands the flourescence at 800 nm. A representative 
Western blot of three independent experiments is shown. For Western Blot analysis GAPDH was used as loading 
control. The relative changes were given as mean + SEM of minimum three independent experiments.  
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Western blot analysis was performed to confirm the localization of CUGBP1 in nucleus and 
cytosol during the time course. Lamin A/C was used as nuclear control as it is thought to be 
involved in nuclear stability, chromatin structure and gene expression and thus an 
appropriate endogenous control for nuclear proteins, whereas GAPDH is ubiquitously 
expressed in the nucleus and the cytosol [272]. Localization during the time course was 
determined by Western blot analysis and exhibited that CUGBP1 is located both in the 
nucleus and cytosol (Fig. 26 B), which stands in line with the staining results in Fig. 24 
[151,262,273]. CUGBP1 was just slightly phosphorylated if overexpressed in A549 cells, 
suggesting that most of CUGBP1 protein was active in its deadenylation functions (Fig. 26 
C). Time course experiments in A549 cells revealed that CUGBP1 mRNA and protein 
expression levels were not altered. The analysis of CUGBP1 expression in SF cells 
confirmed these data and revealed that CUGBP1 was constitutively expressed on mRNA 
level in response to IL-1β treatment (Fig. 27). 
 
Fig. 27: Time course experiments in SF cells. SF cells were induced with 10 ng/ml IL-1β for 24 h. Afterwards 
cell culture medium was replaced by medium without IL-1β and the cells were cultured for further 24 h. Samples 
were collected at different time points. (A) qRT-PCR of mPGES-1, CUGBP1 and mPGES-1 3´UTR mRNA in 
SF0246. Actin was used as control. (B) Western blot analysis of mPGES-1 and CUGBP1 protein expression. A 
representative Western blot of two independent experiments is shown. For Western Blot analysis GAPDH was 
used as loading control. The relative changes were given as mean + SEM of one respectively two independent 
experiments. 
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In stimulated SF0246 cells mPGES-1 and mPGES-1 3´UTR isoform mRNA were increased 
after IL-1β treatment, but rapidly decreased after IL-1β depletion (Fig. 27 A). Protein 
expression was analyzed in SF0246 and SF0252. As shown in Fig. 27 B mPGES-1 protein 
was increased after stimulation, followed by a reduction after IL-1β depletion, whereas no 
changes in CUGBP1 protein expression were observed. 
4.2 miR-574-5p acts as direct decoy to CUGBP1  
4.2.1 CUGBP1 binds to mature miR-574-5p 
 
The various effects of CUGBP1 on mPGES-1 expression could not fully be explained by its 
localization, expression levels or phosphorylation status, assuming that an additional 
regulation may exists. Eiring et al. demonstrated that miR-328 can act as RNA decoy to 
hnRNP E2 [235]. It binds to hnRNP E2 and inhibits its translational repressor activity which 
leads to directly increased expression of hnRNP E2 target genes [236]. Interestingly, GU-rich 
repeat elements are present in the mature form of miR-574-5p representing bona fide 
CUGBP1 binding sites (Fig. 28). miR-574-5p, an intronic miRNA, is encoded by gene 
FAM114A1 and located on the short arm of chromosome 4 (4.p14) in humans on the forward 
strand sense. The alignment of GRE1, GRE2 of mPGES-1 3´UTR and the miR-574-5p 
showed high sequence similarities indicating a potential binding of miR-574-5p to CUGBP1. 
 
Fig. 28: Alignment of RNA sequences of GRE1, GRE2 and miR-574-5p. Sequence homologies (100%) are 
shaded in grey. 
To determine whether CUGBP1 binds to mature miR-574-5p REMSAs were performed using 
radiolabeled miR-574-5p RNA (Fig. 29). As shown in Fig. 29 A, protein-miR-574-5p 
complexes were detected in response to increasing amounts of cytosolic extracts of A549 
cells. The shift of the miR-547-5p RNA probe can be attributed to CUGBP1 because 
overexpression of CUGBP1 led to a stronger RNA shift compared to control cells (Fig. 29 B). 
This shift was abolished by adding excess amount of non-labeled miR-574-5p RNA probe 
(Fig. 29 B). These data indicated that CUGBP1 can bind to the mature form of miR-574-5p. 
In order to verify these results, an additonal experiment was performed using purified 
recombinant CUGBP1 protein (0.08 µg). A protein-RNA complex was observed located 
above the cytosolic/nuclear protein RNA complex. This difference in size was due to the 
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difference in molecular weight of the recombinant protein (~78 kDa) compared to ~50 kDa 
wildtype CUGBP1 (Fig. 29 C) . 
 
Fig. 29: CUGBP1 binds to mature miR-574-5p. (A) Radiolabeled miR-574-5p RNA probe with 10-70 µg 
cytosolic A549 lysates. (B) REMSA of radiolabeled miR-574-5p with 50 µg cytosolic protein. Unlabeled RNA was 
added for competitive shift of miR-574-5p. (C) Radiolabeled miR-574-5p RNA probe with 10 µg cytosolic, or 
nuclear A549 lysates or 0.08 µg purified recombinant CUGBP1 protein. RNA-protein complexes were separated 
by electrophoresis under non-denaturing conditions (6% PAA-Gel). Gels were analyzed on a phosphorimager. A 
representative REMSA of three idependent experiments is shown. 
4.2.2 miR-574-5p expression is upregulated by IL-1β treatment in A549 cells 
 
In this study it was shown that CUGBP1 exerts several functions on mPGES-1 expression 
that could not completely be explained by its translocation and expression pattern. The 
results in Fig. 29 clearly demonstrated that miR-574-5p binds to CUGBP1, which suggests 
that an additional regulation mechanism by the interactions with this miRNA might exist. To 
gain first insights into miR-574-5p expression pattern during the time course experiment 
miRNA expression was analyzed. Fig. 30 shows that miR-574-5p expression was increased 
after 24 h upon IL-1β stimulation. In contrast to mPGES-1 mRNA expression, miR-574-5p 
levels decreased rapidly after IL-1β depletion. This data suggest that the miR-574-5p may be 
cytokine-dependently regulated. 
 4 Results                                  
72 
  
 
Fig. 30: qRT-PCR analysis of miR-574-5p, mPGES-1 and mPGES-1 3´UTR mRNA expression in A549 cells. 
A549 cells were incubated with 5 ng/ml IL-1β for 24 h. Afterwards cell culture medium was replaced by medium 
without IL-1β and the cells were cultured for further 24 h. Samples were collected at different time points. For 
miR-574-5p expression U6 was used as endogenous control. For mPGES-1 and mPGES-1 3´UTR Actin was 
used as control. The relative changes were given as mean + SEM of minimum three independent experiments; 
two way ANOVA, Bonferroni post test. 
4.2.3 Effects of changes in miR-574-5p expression level in A549 lung cancer cells 
 
In order to study the role of miR-574-5p on mPGES-1, miR-574-5p expression levels in A549 
cells were varied. miR-574-5p was overexpressed using miRNA mimics in A549 cells for    
24 h (see chapter 3.2.2). The overexpression was assessed by qRT-PCR (Fig. 31) and led to 
~120 fold increase of miR-574-5p using U6 as endogenous control.    
 
Fig. 31: Quantification of 574-5p-mimcs mediated overexpression in A549 cells via qRT-PCR analysis. The 
cells were transfected with 20 pmol/µl miR-574-5p mimics or negative control, respectively and collected 24 h 
after transfection. U6 was used as endogenous control. The relative changes were given as mean + SEM of 
minimum three independent experiments; t-test, p* < 0.05. 
It was demonstrated that miR-574-5p and mPGES-1 were induced by IL-1β treatment after 
24 h (Fig. 30) and miR-574-5p was notably downregulated without IL1-β. Therefore, the 
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influence of miR-574-5p oe 24 h after IL-1β stimulation was investigated. qRT-PCR analysis 
revealed an increase of IL-1β mediated induction of mPGES-1 3´UTR isoform in response to 
miR-574-5p oe (Fig. 32 A).  
 
Fig. 32: Effect of miR-574-5p oe on mPGES-1 induction by IL-1β. 24 h after mimics transfection (20 pmol/µl) 
A549 cells were induced with 5 ng/ml IL-1β for further 24 h. (A) qRT-PCR analysis of mPGES-1 and mPGES-1 
3´UTR mRNA expression in response to miR-574-5p oe. Actin was used as control for mPGES-1 and mPGES-1 
3´UTR mRNA expression. U6 was used as endogenous control for miR-574-5p expression. (B) Western blot 
analysis of mPGES-1 protein expression overexpressing miR-574-5p. A representative Western blot of three 
independent experiments is shown. For Western blot analysis GAPDH was used as loading control. The relative 
changes were given as mean + SEM of minimum three independent experiments; t-test, p* < 0.05; **p < 0.01. 
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In contrast to that, the mature mPGES-1 mRNA transcript was not affected by IL-1β 
mediated induction in response to miR-574-5p oe (Fig. 32 A). On protein level a significant 
upregulation on IL-1β mediated induction of mPGES-1 was observed in response to miR-
574-5p oe (Fig. 32 B), indicating that miR-574-5p oe inhibited CUGBP1-mediated 3´UTR 
mRNA degradation and mPGES-1 protein translational repression in the cytosol. However, 
the increased level of mPGES-1 3´UTR variant indicates that the alternative splicing 
mediated by CUGBP1 in the nucleus is not affected by the mature miR-574-5p. It was 
interesting to elucidate if decreased levels of miR-574-5p showed the opposite effects on 
mPGES-1 expression. Next miR-574-5p expression was depleted using specific miR-574-5p 
LNAs™ (see chapter 3.2.3). The knockdown efficiency of miR-574-5p was assayed by qRT-
PCR and revealed a significant reduction (~ 90%) in A549 cells after 24 h (Fig. 33). 
 
Fig. 33: qRT-PCR analysis of LNA-mediated knockdown of miR-574-5p. A549 cells were transfected with 40 
pmol/µl LNAs™ and collected 24 h after transfection. The relative changes were given as mean + SEM of 
minimum three independent experiments; t-test, p* < 0.05; **p < 0.01, ***for p<0.001. 
As shown in Fig. 34 A, induced mPGES-1 mature mRNA expression was not affected by 
∆miR-574-5p, whereas induced mPGES-1 3´UTR isoform was significantly reduced in 
response to ∆miR-574-5p (Fig. 34 A).  
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Fig. 34: Influence of ∆miR-574-5p on induced mPGES-1 expression. A549 cells were transfected with miR-
574-5p LNA™ (40 pmol/µl) and 24 h after transfection induced with 5 ng/ml IL-1β for 24 h. (A) qRT-PCR analysis 
of mPGES-1 and mPGES-1 3´UTR mRNA expression. Actin was used as control. (B) Western blot analysis of 
mPGES-1 protein expression. A representative Western blot of three independent experiments is shown. For 
Western blot analysis GAPDH was used as loading control. The relative changes were given as mean + SEM of 
minimum three independent experiments; t-test, p* < 0.05; **p < 0.01. 
Comparable to the mRNA level, the IL-1β induced mPGES-1 protein expression was not 
affected in response to ∆miR-574-5p (Fig. 34 B). However, relative protein expression 
showed a slight decrease in mPGES-1 protein level. These experiments stand in line with the 
results obtained with miR-574-5p oe and CUGBP1 oe suggesting that mPGES-1 expression 
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in the cytosol is regulated by the interaction between miR-574-5p and CUGBP1. The results 
obtained in Fig. 25 demonstrated that ∆CUGPB1 led to a significant increase of IL-1β 
induced cell proliferation, whereas CUGBP1 overexpression decreased significantly A549 
cell proliferation. In the next step, it was interesting to elucidate if miR-574-5p oe shows a 
similar effect on A549 cell proliferation as ∆CUGBP1. miR-574-5p was overexpressed in 
unstimulated A549 cells and led to no significant changes in cell proliferation (Fig. 35 A). 
Interestingly, miR-574-5p mimics in stimulated cells revealed a significant up regulation in IL-
1β induced cell proliferation (Fig. 35 B), whereas a knockdown of miR-574-5p led to a 
significant decrease in induced cell proliferation (Fig. 35 B). The data suggest that CUGBP1 
acts as a proliferation inhibitor and miR-574-5p acts as a direct decoy to CUGBP1 by 
inhibiting its functions. 
 
Fig. 35: Effect of miR-574-5p overexpression (20 pmol/µl) and knockdown (40 pmol/µl) on IL-1β induced 
cell proliferation in A549 cells analyzed by MTT cell proliferation assay. MTT cell proliferation assay was 
performed in A549 cells 24 h after transfection induced with and without IL-1β (5 ng/ml) for 24 h with (A) miR-574-
5p oe w/o IL-1β  (B) miR-574-5p oe and ∆miR-574-5p with IL-1β. The relative changes were given as mean          
+ SEM of minimum three independent experiments; t-test, p* < 0.05. 
Next it was investigated whether the effect of mPGES-1 regulation alone is responsible for 
the changes in proliferation mediated by CUGBP1 and miR-574-5p. Therefore, a MTT cell 
proliferation assay was performed using an mPGES-1 inhibitor (CIII) or DMSO control, 
respectively [53,57]. As shown in Fig. 36 treatment with the mPGES-1 inhibitor led to no 
significant changes in A549 cell proliferation neither for the control nor for ∆CUGBP1/miR-
574-5p oe. Determination of cell viability analyzed in Fig. 22 demonstrated a decreased cell 
viability of CUGBP1 overexpression cells. The MTT cell proliferation analysis indicate that 
 4 Results                                  
77 
  
there might be an additional pathway that is regulated by the interplay of CUGBP1 and miR-
574-5p, as mPGES-1 regulation alone is not responsible for changes in cell proliferation. 
This stands in line with the results in Fig. 25 that IL-1β treatment led to an increased 
mPGES-1 expression but not an increased cell proliferation. 
     
Fig. 36: Cell proliferation in A549 cells treated with 10 µM mPGES-1 inhibitor (CIII) in combination with 
∆CUGBP1 (20 pmol/µl) and miR-574-5p oe (20 pmol/µl) analyzed by MTT cell proliferation assay. MTT cell 
proliferation assay was performed in A549 cells 24 h after transfection induced with IL-1β (5 ng/ml) for further 24 h 
with (A) ∆CUGBP1 (B) miR-574-5p overexpression. The relative changes were given as mean + SEM of four 
independent experiments; t-test. 
4.3 miR-574-5p promotes lung tumour growth in vivo  
4.3.1 Characterization of the stable miR-574-5p oe A549 cell line 
 
It is known that tumour invasion and metastasis is regulated by miR-574-5p in non-small cell 
lung cancer [274]. Furthermore, it was shown that mPGES-1 expression and PGE2 formation 
determines tumour growth of lung cancer cells in vivo [70]. To gain more detailed insights 
into the mechanisms behind the tumour progression linked with miR-574-5p in vivo and to 
unravel potential links with enhanced PGE2 synthesis, miR-574-5p was stably overexpressed 
in the human A549 lung cancer cell line using lentiviral particles. The stable transfection was 
more useful due to long-term gene expression required in the mouse xenocraft model, which 
was established in cooperation with the lab of Prof. Paola Patrignani (University Chieti, Italy). 
The overexpression of miR-574-5p was assessed by qRT-PCR analysis. miR-574-5p was 
significantly upregulated to ~33 fold (Fig. 37 A), but much lower than transient miR-574-5p 
oe. Since there can be variations between stable and transient transfection due to a number 
of factors like position, site of integration and copy number, the stable cell line was 
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characterized. On mRNA level no significant changes could be observed for IL-1β induced 
mPGES-1 and mPGES-1 3´UTR isoform (Fig. 37 C). However, MTT cell proliferation assay 
did not show an increase in A549 cell proliferation in response to miR-574-5p (Fig. 37 B) in 
contrast to observations in transient A549 miR-574-5p oe cells.  
 
Fig. 37: Characterization of stable miR-574-5p oe A549 cell line. (A) qRT-PCR analysis of miR-574-5p- 
overexpressing A549 cell line. U6 was used as endogenous control. The relative changes to control samples 
were given as mean + SEM of five independent experiments. (B) MTT cell proliferation assay. MTT cell 
proliferation assay was performed in A549 cells induced with IL-1β (5 ng/ ml) for 24 h. (C) qRT-PCR analysis of 
mPGES-1 3´UTR and (C) mPGES-1 mRNA expression in response to miR-574-5p oe. Actin was used as control. 
The relative changes were given as mean + SEM of three independent experiments. The relative changes were 
given as mean + SEM of three independent experiments; t-test, p* < 0.05. 
4.3.2 miR-574-5p enhances lung tumour growth in vivo
 
 
Together with our cooperation partner in Italy (Prof. Paola Patrignani and her lab members, 
University Chieti) mPGES-1 protein expression and PGE2 production in stable A549 miR-
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547-5p cells was analyzed. It was shown that A549 miR-574-5p oe cells produced enhanced 
PGE2, which was associated with increased mPGES-1 protein expression in response to IL-
1β treatment (Fig. 38 A/B).  This supported the theory that the dysregulated mPGES-1 
expression in miR-574-5p oe cells explained enhanced PGE2 production in vitro. 
 
Fig. 38: miR-574-5p increases mPGES-1 protein and PGE2 production. (A) Stably transduced A549 cells were 
stimulated with IL-1β (5 ng/ml) for 24 h. mPGES-1 protein expression in stable A549 miR-574-5p oe and control 
cells. GAPDH was used as loading control. A representative Western blot of three idependent experiments is 
shown. (B) PGE2 production in A549 control and miR-574-5p oe cells. The relative changes to control samples 
were given as mean + SEM of three independent experiments, t-test, p* < 0.05, **p < 0.01. 
For deeper insights into the mechanisms behind the tumour progression linked with miR-574-
5p in vivo demonstrated by Zhou et al. [275], CD-1® Nude mice were chosen to address the 
potential tumourigenic effect of miR-574-5p. These experiments were performed in the lab of 
Prof. Paola Patrigniani in Italy. PGE2 measurements demonstrated a significant increase in 
PGE2 production in A549 miR-574-5p oe cells in response to IL-1β, which was attributed to 
upregulation of mPGES-1 expression in response to miR-574-5p oe. Therefore, the selective 
mPGES-1 inhibitor CIII [53] was used to evaluate whether the stimulation of tumour growth 
by miR-574-5p in vivo is due to increased PGE2 formation. A549 control cells or A549 miR-
574-5p oe cells were resuspended in PBS and then subcutaneously (s.c.) injected into both 
dorsal flanks of mice to establish a model of tumour-bearing mice (Fig. 39 A). Tumour growth 
and weight was recorded over 4 weeks.  
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Fig. 39: miR-574-5p promotes tumour growth in vivo. (A) Experimental design of mouse experiments. CD-1® 
Nude Mice were housed under specific pathogen-free conditions. A549 control cells or A549 miR-574-5p oe cells 
were s.c. injected into both dorsal flanks of mice. The mPGES-1 inhibitor (CIII) or vehicle control, respectively 
were administered every day, until sacrifice. Control mice received A549 control cells or A549 miR-574-5p oe 
cells and were treated with vehicle, once every day by i.p. injection from tumour cell implantation until sacrifice. A 
group of mice received A549 control cells or A549 miR-574-5p oe cells and were treated with CIII once every day, 
by i.p. injection from tumour cell implantation until sacrifice. Tumour growth and body weight were monitored from 
tumour cell implantation until sacrifice. Mice were sacrificed after 4 weeks from tumour cell implantation, 30 min 
after the last treatment. Plasma, Lungs and tumours were collected for further analysis. (B & C): Nude mice with 
A549 control cells (A549 control) or A549 cells overexpressing miR-574-5p (A549 miR-574-5p oe) (5x106/100µl 
PBS). A549 control cells-injected or miR-574-5p oe cells-injected mice were treated with vehicle or with CIII 
(50mg/kg) once every day by i.p. injection from tumour cell implantation until sacrifice. (B) PGE2 measurement 
after sacrifice (B) tumour growth (C) tumour weight. At each experimental time-point, **p<0.001 vs. A549 control 
vehicle and A549 miR-574-5p oe CIII 50mg/kg, i.p. *p<0.01 vs. A549 control vehicle; §p<0.05 vs. A549 miR-574-
5p oe CIII 50mg/kg, i.p. ANOVA analysis and Newman-Keuls multiple comparison test. 
Cells overexpressing miR-574-5p exhibited enhanced tumourigenic ability compared to 
control cells starting from day 3 after tumour cell implantation (Fig. 39 B). The treatment with 
the mPGES-1 inhibitor CIII prevented this effect. In mice injected with A549 control cells, 
treatment with the mPGES-1 inhibitor CIII did not significantly affect tumour growth in vivo. At 
the day of sacrifice the animals were killed and the tumours dissected and weighted. 
Accordingly to the volume, the weight of the tumours was significantly enhanced in mice 
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injected with A549 miR-574-5p oe cells compared to the mice injected with A549 control cells 
(Fig. 39 C). Moreover, the treatment with the mPGES-1 inhibitor CIII every day from tumour 
cell implantation until sacrifice significantly prevented this effect. In mice injected with A549 
control cells, the treatment with the mPGES-1 inhibitor CIII did not significantly affect tumour 
weight at sacrifice. These results indicate that A549 miR-574-5p oe cells and elevated PGE2 
levels in this cell type are associated with enhanced tumour growth in vivo in nude mice. 
4.4 miR-574-5p is upregulated in tumours of NSCLC patients stage II-III 
 
Recently, miR-574-5p has been described as a potential important serum-based biomarker 
for early-stage non-small cell lung cancer cells (NSCLC) I-II [239]. In that microarray of Foss 
et al. miR-574-5p was upregulated to 2.17 fold in serum normalized to control. Keller and 
coworkers demonstrated a 3.59 fold upregulation of miR-574-5p in blood cells from lung 
tumour in response to blood cells from healthy controls [276]. In IL-1β stimulated A549 cells 
with transient miR-574-5p overexpression the proliferation was increased (Fig. 35). To reveal 
novel tumour-related miR-574-5p expression in NSCLC miR-574-5p expression in tumour 
and non-tumour, lung tissue of four NSCLC patients was analyzed. (The samples were kindly 
provided by Dr. R. Savai, Max Planck Institute for Heart and Lung Research in Bad Nauheim, 
Germany). Three of them were histological categorized as adenocarcinoma and one as 
squamous carcinoma. In tumours there was a significant increase in miR-574-5p expression 
assessed by qRT-PCR (T:24.5-28.2 Ct values) (NT:28-33.5 Ct values) (Fig. 40).  
 
Fig. 40: miR-574-5p expression is upregulated in tumours of NSCLC patients. qRT-PCR analysis of miR-
574-5p expression. miRTC was used as endogenous control. The relative changes to control samples were given 
as mean + SEM of four independent experiments; t-test, p* < 0.05. 
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The expression values were normalized to miRTC control, which permits a suitable 
assessment of reverse-transcription performance. It has been shown that miRNAs 
expression levels can be differently regulated in lung cancer [277,278]. Therefore, a selection 
of other miRNAs was tested as endogenous control. U6, miR-16 and Snord-72 were no valid 
controls as their expression level changes in lung cancer. qRT-PCR analysis of U6, miR-16 
and Snord-72 revealed a strong regulation in the lung cancer tissue of the patients. The 
different miR-574-5p expression profiles between NSCLC and healthy tissue and between 
the subtypes/stages of NSCLC may have potential implications in the pathogenesis of this 
cancer. This preliminary data demonstrated that there may be an association between miR-
574-5p upregulation in NSCLC and survival in lung cancer patients.  
 
 
 5 Discussion                                  
 
83 
 
5 Discussion 
5.1 CUGBP1 regulates mPGES-1 expression multifunctional via alternative splicing, 
mRNA turnover and translational repression 
 
There is huge evidence addressing increased prostaglandin production in tumour 
development and progression. Elevated levels of mPGES-1 and PGE2 have been found in 
different types of cancers, including prostate cancer, colon cancer and non-small cell lung 
cancer (NSCLC) [11,65]. Different studies demonstrated that the mPGES-1 promoter alone 
cannot account for the strong induction of mPGES-1 by cytokines suggesting that additional 
post-transcriptional mechanisms might be involved such as alternative splicing, mRNA 
turnover or translational control. It is known that the expression of mPGES-1 can be 
controlled by several transcription factors (Egr-1, NF-κB, AP-1) and MAP kinases [279,280]. 
Moreover, it was shown that the 3´UTR of mPGES-1 contains two GREs which could 
function as cis regulatory elements recruiting trans-acting factors which may regulate mRNA 
level, translation or localization [254]. Until now nothing is known if alternative splicing is 
involved in the upregulation of mPGES-1 expression observed in inflammation and cancer.  
Since defects in splicing are often correlated with diseases and involved in the progression of 
cancer [116,117], changes in the splicing patterns of mPGES-1 3´UTR in A549 cells, HeLa 
cells and synovial fibroblast from RA patients were investigated. Analysis of mPGES-1 
splicing pattern in these cell lines revealed the existence of a ~300 bp alternatively spliced 
3´UTR transcript (Fig. 13). Sequence analysis of this mPGES-1 3´UTR isoform exhibits that 
the middle part of mPGES-1 3´UTR was spliced out (NM_004878.4). Interestingly, both sites 
of mPGES-1 3´UTR intron are flanked with a GRE representing binding sites for RNA-
binding protein CUGBP1 [195]. In this study, it was demonstrated that CUGBP1 binds 
sequence specifically to both GREs of mPGES-1 3´UTR.  
Multiple regulatory functions of CUGBP1 on mRNA processing including mRNA splicing, 
destabilization and translation of mRNAs have been reported so far [151]. In line with that, 
we have shown that CUGBP1 is responsible for mPGES-1 3´UTR splicing and both GREs 
within the 3´UTR are necessary for alternative splicing (Fig. 17). The GREs were responsible 
for decreased luciferase activity analyzed by reporter gene assays. The effect was abolished 
by the sequential and double deletion of the GREs. Furthermore, RT-PCR analysis 
confirmed these data as there was no 3´UTR splice product detectable by the sequential or 
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double deletion of GREs. These data suggest mPGES-1 3´UTR splicing was mediated by 
CUGBP1 whereby both GREs are essential for splicing. These findings correspond with 
published data. It was shown that aberrant regulation of insulin receptor (INSR) was due to 
alternative splicing (skipping of exon 11) mediated by CUGBP1 [281]. Furthermore, CUGBP1 
binds to a GU-rich sequence in intron 2 of muscle-specific chloride channel 1 (CLCN1) in 
DM1, which leads to intron retention and a PTC-containing mRNA transcript that is rapidly 
degraded [188,189]. However, additional studies are required to clarify the exact mechanism 
by which CUGBP1 binding to its RNA targets regulates alternative splicing events. It could 
also involve conformational changes in the RNA structure or competition with other splicing 
factors to promote or repress the spliceosome formation. Furthermore, mPGES-1 3´UTR has 
predicted binding sites for hnRNP E2, HuR and muscleblind-like splicing regulator (MBNL) 1, 
which play a role in many regulatory processes. It was shown that abnormal alternative 
splicing of CLCN1 and INSR caused myotonia and insulin resistance and was due to an 
imbalance of the two RNA-binding proteins MBNL and CUGBP1 that act in an antagonistic 
manner. In addition, it has been shown that MBNL1 binds directly to CUG and CCUG repeat 
RNAs [282,283]. Also, it has been shown that competition between CUGBP1 and HuR 
modulates MYC translation and intestinal epithelium renewal [284]. Competition of CUGBP1 
and calreticulin in the regulation of p21 translation determines cell fate [200]. ABLIM1 splicing 
is abnormal in skeletal muscle of patients with DM1 and regulated by the interplay between 
MBNL, CELF1, 2 and 6 and PTBP1 [285]. It seems that aberrant alternative splicing 
mediated by CUGBP1 occurs in the nucleus [286]. Repression of nuclear CUGBP1 activity 
could rescue CUGBP1-regulated alternative splicing defects in skeletal muscle models of 
myotonic dystrophy [287]. 
The reporter gene assays in HeLa cells demonstrated that CUGBP1 binding to GREs in the 
mPGES-1 3´UTR reduced gene expression maybe mediated by reduced mRNA stability. 
Indeed, actinomycin D treatment to address mRNA stability resulted in a substantial 
decrease in the amount of mPGES-1 isoform mRNA, in contrast to mature mPGES-1 mRNA, 
which still contains two GREs in the 3´UTR (Fig. 18). This data suggest that CUGBP1 might 
preferably regulate mRNA stability of the mPGES-1 3´UTR isoform. Highly conserved GU-
rich elements composed of a consensus sequence UGUUUGUUUGU or GU-repeat 
sequence can be targeted by CUGBP1 and have been identified as sequence elements 
enriched in the 3´UTR of short-lived transcripts, which encode important regulators of cell 
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cycle and apoptosis [177]. It has been shown that cytosolic GU-containing mRNA transcripts 
are rapidly degraded by CUGBP1 dependent recruitment of PARN deadenylases [264,288]. 
CUGBP1 interacts with PARN in HeLa cytosolic cell extracts to promote deadenylation of 
Fos and TNF transcripts [264]. Furthermore, siRNA-mediated knockdown of CUGBP1 in 
HeLa cells and myoblasts led to the stabilization of a set of normally rapidly degraded 
transcripts bound by CUGBP1 to GREs and GU-repeats [177,195,261].  
mRNA transcripts with premature termination codons are highly instable and rapidly 
degraded by mRNA decay mechanisms such as NMD. The spliced mPGES-1 3´UTR isoform 
contains a PTC and is therefore a potential NMD target [263]. UPF1 knockdown experiments 
were performed to inhibit NMD and to determine whether CUGBP1 or UPF1-mediated 
mRNA decay pathways is responsible for 3´UTR isoform degradation. No changes in mRNA 
expression of mPGES-1 and the 3´UTR splice variant were observed depleting UPF1, 
suggesting that UPF1-independent mRNA degradation of mPGES-1 isoform is mediated by 
CUGBP1, which recruits PARN to cytosolic GU-containing transcripts (Fig. 18). Interestingly, 
mature mPGES-1 3´UTR transcript is not affected by GU-mediated mRNA decay, suggesting 
that there are additional regulatory mechanisms that prevent the correctly spliced mature 
transcript from GU-mediated mRNA decay in the cytosol. This observation stands in line with 
CUGBP1 overexpression where only a slight decrease of 3´UTR isoform was observed but 
mature mPGES-1 mRNA was not affected (Fig. 23). Taken together, these data suggest that 
(i) nuclear CUGBP1 acts as splice factor for mPGES-1 3´UTR by binding to both GREs, 
thereby inducing alternative splicing in the 3´UTR, (ii) cytosolic CUGBP1 acts together with 
PARN as RNA destabilizing factors by binding to the GU consensus sequence of mPGES-1 
3´UTR isoform, (iii) cytosolic CUGBP1 preferably seems to reduce dysregulated 3´UTR 
isoform, whereas correctly spliced mPGES-1 mRNA is not degraded or maybe stabilized by 
other RBPs. Until now, whether these functions of CUGBP1 are directly linked together or 
compartmentally independently regulated remains unclear. There can be a network of 
additional regulation mechanisms and RBPs that regulate mPGES-1 mRNA turnover and 
translation. 
Time course experiments in A549 cells were performed with ∆CUGBP1 to address the 
potential destabilizing effect of CUGBP1 on mPGES-1 expression in an inflammatory 
context. Depletion of CUGBP1 significantly increased mPGES-1 3´UTR isoform mRNA 
expression, whereas mature mPGES-1 mRNA was less affected. These data demonstrate 
the destabilizing effect of CUGBP1 on the splice variant. However, mPGES-1 protein 
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expression was also upregulated by ∆CUGBP1 (Fig. 20) and in contrast downregulated in 
response to CUGBP1 oe (Fig. 23). CUGBP1 depletion had a stronger effect on mPGES-1 
protein than on mRNA expression, suggesting that (i) mRNA turnover increases mPGES-1 
protein and (ii) CUGBP1 may additional acts as translational repressor for mPGES-1. This 
stands in line with the results of Yu and coworkers who demonstrated that CUGBP1 acts as 
translational repressor for occludin [151]. In this study, they showed that CUGBP1 binds to 
3´UTR of occludin through increasing recruitment of tagged occludin mRNA to processing 
bodies (PBs). Consistent with these findings, CUGBP1 has also been shown to repress 
CDK4 translation by increasing CDK4 mRNA translocation to PBs [289]. Furthermore, 
CUGBP1 and HuR regulate E-cadherin translation by altering recruitment of E-cadherin 
mRNA to PBs thereby modulating epithelial barrier function [271]. To prove the hypothesis 
that CUGBP1 might repress translation of mPGES-1 mRNA due to recruiting mPGES-1 
mRNA in PBs the distribution of CUGBP1 and PBs was examined by immunofluorescence 
staining. CUGBP1 extensively colocalizes with the prominent PB marker DCP1a (Fig. 24). To 
investigate whether PB formation plays a crucial role in mPGES-1 translation GW182 was 
silenced, which is crucial for PB formation [270]. As expected the mature mPGES-1 mRNA 
was not affected by GW182 knockdown, whereas the protein expression was significantly 
increased (Fig. 24), indicating an important role of CUGBP1 acting as translational repressor 
for mPGES-1 protein expression in combination with PB formation mediated by PB marker 
GW182. The exact mechanisms by which PBs repress the translation of resident mRNAs 
need to be further investigated. It remains still unclear how exactly mPGES-1 protein is 
increased by CUGBP1 depletion. Whether it is only due to mRNA turnover, PB formation or a 
combination of both needs to be further investigated. PBs contain many proteins that are 
associated with RISC complex and mRNA decay: All four Ago proteins, GW182, RCK and 
MOV10 (two RNA helicases), DCP1 and DCP2 (decapping enzymes), CCR4–CAF-1–Not 
complex (mRNA deadenylation factors), Dhh1/RCK/p54, Pat1, Scd6/RAP55, Edc3, and the 
LSm1–7 complex (activators of decapping) and XRN-1 (exonucleases) [290,291,292]. 
Further studies investigating Ago or RCLK protein would be helpful to understand the exact 
regulation of PB recruitment, association with mRNA turnover and translation. 
PGE2 is highly expressed at sites of inflammation and cancer and though it might be involved 
in the progression an onset of many types of cancer. It is known that genetic deletion of 
mPGES-1 reduced the synthesis of inducible PGE2 and markedly suppressed intestinal 
tumour formation in Apc∆14 mice [71]. Therefore, PGE2 formation was analyzed in response 
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to ∆CUGBP1. Like mPGES-1 protein expression PGE2 release was also significantly 
increased by CUGBP1 knockdown, assuming that mPGES-1 protein upregulation increases 
its enzymatic product PGE2 (Fig. 20). Contrary to mPGES-1 protein expression, PGE2 levels 
were significantly reduced after IL-1β depletion, suggesting that COX-2 or PGH2 might be 
affected by CUGBP1. mPGES-1 expression is often concomitantly induced in response to 
COX-2 overexpression, thus, contributing to the efficient generation of PGE2 [11]. COX-2 has 
no binding site for CUGBP1. Hence, CUGBP1 knockdown had no influence on COX-2 
expression levels. The downregulation of PGE2 was attributed to the strong decrease in 
COX-2 mRNA and protein expression after IL-1β depletion, leading to decreased PGH2 
levels (Fig. 20). These data demonstrate the specific regulation of mPGES-1 expression by 
CUGBP1.  
To sum up CUGBP1 has multiple functions on mPGES-1 expression. Here, it was 
demonstrated that CUGBP1 is responsible for mPGES-1 3´UTR splicing. Besides its role as 
splice factor, CUGBP1 binds to GREs within 3´UTR of short-lived transcripts and promotes 
GU-dependent mRNA decay of the spliced 3´UTR isoform. Furthermore, it was shown that 
CUGBP1 represses mPGES-1 translation, obviously by recruiting mPGES-1 mRNA to PBs.  
5.2 New insights into CUGBP1-dependent mPGES-1 regulation in RA 
 
RA is a systemic autoimmune disease primarily affecting the joints of patients and leading to 
their progressive destruction. This joint destruction is a unique and most prominent symptom 
of RA that not only distinguishes the disease from other arthritic conditions [293]. RA is 
associated with typical symptoms such as pain and inflammation. During active RA immune 
cells like monocytes, macrophages, mast cells, T and B cells infiltrate the synovial joints. The 
immune cells interact in a complex manner, which leads to the release of pro-inflammatory 
mediators [294] (Fig. 41). High levels of pro-inflammatory cytokines including TNFα, IL-1β 
and IL-17 can be detected in fluids and synovium in the joints of RA patients. It is known that 
these mediators play an important role in the initiation and development of RA [295]. 
Furthermore, they are associated with the production of biologically active lipid mediators like 
PGE2. It has been shown that mPGES-1 in contrast to cPGES and mPGES-2 is markedly 
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upregulated in synovial tissue from RA patients [296]. These findings suggest that increased 
levels of mPGES-1 during active RA play a major role in the production of PGE2, while 
mPGES-2 and cPGES may rather have a minor role. Until today selective COX-2 inhibitors 
are extensively used for the treatment of RA [297]. But several clinical trials demonstrated 
that some COX inhibitors, except ASS and Naproxen, increase the risk of cardiovascular 
events [24]. In order to reduce the side effect of COX inhibitors, selective suppression of 
mPGES-1-derived PGE2 production seems to be an attractive therapeutic alternative. It was 
shown that mPGES-1 deletion in mice leads to significant decrease in PGE2 levels and 
increases in PGI2 with no alterations in blood pressure or thrombosis [75].  
 
Fig. 41: Model of regulation of mPGES-1 expression in rheumatoid synovial fibroblasts. COX-2 and 
mPGES-1 are induced by stimulation of pro-inflammatory cytokines e.g. IL-1β. Abundant PGE2 production at the 
inflammation sites of RA is caused by the coordinated upregulation of mPGES-1 and COX-2. PGE2 enhances 
mPGES-1 expression associated with increase of cyclic AMP (cAMP) via the EP2 and EP4 receptors. The 
positive feedback regulation of mPGES-1 expression by PGE2 may play an important role in the vicious circle of 
inflammation associated with RA, modified [298]. 
Investigation of mPGES-1 splicing pattern in SF cells demonstrated the presence of the 
mPGES-1 3´UTR isoform that may be correlated to the inflammatory status of synovial 
fibroblasts derived from RA patients. In the model cell line A549, it was shown that CUGBP1 
is responsible for mPGES-1 expression regulation by alternative splicing and GU-mediated 
mRNA degradation of the spliced mPGES-1 3´UTR isoform. CUGBP1 levels were 
manipulated to investigate the influence of CUGBP1 on mPGES-1 expression in SF cells. 
According to the results in A549 cells the siRNA-mediated knockdown of CUGBP1 did not 
alter mPGES-1 mRNA levels (Fig. 21), whereas the destabilizing effect of CUGBP1 on the 
3´UTR isoform was abolished. Preliminary data showed that mPGES-1 protein was slightly 
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increased in SF0246 by ∆CUGBP1. However, the knockdown efficiency of CUGBP1 was 
weaker than in A549 cells. The results would match with those in A549 cells that translation 
repression of mPGES-1 is mediated by CUGBP1. With these results it will be interesting to 
elucidate further approaches in CUGBP1-dependent mPGES-1 regulation and PGE2 
production as they may be important in RA development and treatment. 
5.3 CUGBP1 is constitutively expressed and not regulated via its translocation  
 
CUGBP1 is a multifunctional protein and involved in different molecular processes with 
specific functions in different cellular compartments [109,186]. Therefore, it was investigated 
how CUGBP1 is localized, regulated and expressed in A549 cells to unravel the multiple 
influence of CUGBP1 on mPGES-1 expression. Investigation of mRNA and protein 
expression levels of CUGBP1 in A549 cells and in RASF revealed that CUGBP1 is 
constitutively expressed and not regulated by cytokine IL-1β or altering mPGES-1 expression 
levels (Fig. 26 & Fig. 27). Immunofluorescence stainings and Western blot analysis showed 
that CUGBP1 is located in the nucleus as well as in the cytoplasm, which stands in line with 
previous work of Timchenko and coworkers [109].  
CUGBP1 function is not only dependent from its localization but also by its phosphorylation 
status [202,203]. CUGBP1 protein expression was increased in the muscle of myotonic 
dystrophy (DM) patients and DM mouse models in which nuclear CUGBP1 was stabilized by 
PKC-mediated phosphorylation [199,281]. Until now it is not known how PKC is activated. In 
addition, phosphorylation of CUGBP1 is altered by activation of GSK3β signaling in DM 
[181]. However, the mechanism of PKC and GSK3β activation by expanded repeat RNAs 
remains unclear. It was shown that for binding to the G/C rich element of p21 and C/EBPβ 
mRNAs, CUGBP1 has to be hyperphosphorylated and accumulated in the nucleus [200,204]. 
In contrast, the cytosolic deadenylation activity to GREs is activated by 
dephosphophorylation [202]. The deadenylation activity leads to a degradation of the target 
mRNA and consequently a decreased synthesis of the encoded protein by removal of the 
translation template. In accordance with this, analysis of phosphorylation status of CUGBP1 
revealed no phosphorylation in A549 cells, HeLa cells and RASF during time courses or 
CUGBP1oe/∆CUGBP1 experiments (data not shown). CUGBP1 was just slightly 
phoshorylated in A549 cells when it was overexpressed (Fig. 26). It was shown that 
regulation of CUGBP1 expression may be crucial in NSCLC tissue, where CUGBP1 was 
highly expressed and there its overexpression was associated with the progression of 
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NSCLC [205,208,209]. The various effects of CUGBP1 on mPGES-1 expression could not 
fully be explained by its cellular translocation, changes in expression levels or 
phosphorylation status of CUGBP1, suggesting that an additional regulation mechanism may 
exists. 
The capacity of CUGBP1 to bind to one or more GU-rich elements could depend on the 
presence or absence of other proteins in a multimeric functional complex. The association 
with these cofactors could be affected by the hyper- or dephosphorylation status of CUGBP1 
or by the expression of the cofactor(s). Hence, the change between G/C-rich binding 
associated with translational control, possibly via eIF2 binding [299], and GU-rich binding 
associated with deadenylation and mRNA degradation appears to be controlled by signaling 
pathways that activate or inactivate appropriate kinases. Until now the amino acids whose 
phosphorylation is required for G/C-rich binding and those that must be dephosphorylated to 
activate the deadenylation process have not been identified. Therefore, whether these 
binding and functional characteristics are mutually exclusive cannot be decided yet. 
5.4 miR-574-5p acts as RNA decoy to CUGBP1  
 
Previously, a new mechanism for miRNAs has been identified for miR-328. It has been 
shown that miR-328 can bind to a regulatory repressing protein thereby acting as decoy 
leading to activation of gene expression [235,236]. This is, in contrast to the classical 
function of miRNAs as silencers. miR-574-5p harbors the GU-rich elements (GREs) in its 
mature form thereby representing bona fide binding sites for the RNA-binding CUGBP1 (Fig. 
28). Therefore, we hypothesized that miR-574-5p may act as RNA-decoy for CUGBP1. We 
could demonstrate that CUGBP1 binds specific to miR-574-5p, assuming that there may be a 
regulation of mPGES-1 by the interaction of miR-575-5p and CUGBP1 (Fig. 29). 
Interestingly, different studies demonstrated that upregulation of miR-574-5p confer with an 
enhanced tumour progression in human lung cancer, which correlates with an elevated 
mPGES-1 expression level in this type of cancer [300]. In addition to this, miR-574-5p has 
been described as a serum-based miRNA biomarker for early stage NSCLC [239]. We 
demonstrated that miR-574-5p and mPGES-1 mRNA were upregulated by IL-1β treatment 
after 24 h and notably downregulated in response to IL-1β removal (Fig. 30). Furthermore, 
miR-574-5p levels in A549 cells were manipulated to investigate the effects of the balance 
between miR-574-5p and CUGBP1 on mPGES-1 expression. Overexpression of miR-574-5p 
in A549 cells using miR-574-5p mimics supported the theory that miR-574-5p acts a direct 
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decoy for CUGBP1 binding. During IL-1β mediated induction mPGES-1 3´UTR isoform was 
significantly induced in response to miR-574-5p oe. The mature induced mPGES-1 transcript 
was not affected by miR-574-5p overexpression, whereas IL-1β induced mPGES-1 protein 
expression was significantly upregulated (Fig. 32). Additionally, knockdown of miR-574-5p in 
A549 cells led to a significant decrease of IL-1β induced mPGES-1 3´UTR isoform, where in 
contrast the mature mPGES-1 mRNA was not affected (Fig. 34). Unfortunately, a decrease 
of induced mPGES-1 protein expression was not detected, which could be due cell 
homoeostasis. If miR-574-5p is not present in A549 cells there is no need for CUGBP1 to 
reduce mPGES-1 protein levels.  
 
 
Fig. 42: Model of the interaction between miR-574-5p and CUGBP1 on mPGES-1 expression. 
 
 
 5 Discussion                                  
92 
  
Taken together our study revealed that miR-574-5p has a perfect binding site for CUGBP1 
and acts as RNA decoy to CUGBP1 as it is illustrated in the model in Fig. 42. The stimulatory 
effects of miR-574-5p on mPGES-1 expression suggested a mechanism that does not follow 
the canonical function of miRNAs to inhibit gene expression via binding to the 3´UTR of the 
target gene and stands in line with previous results of Saul et al. 2016 [236]. 
5.4.1 A549 cell proliferation is regulated by the balance of CUGBP1 and miR-574-5p  
 
Cell proliferation, migration and invasion are commonly required for metastatic progression 
[301,302]. Assays that determine metabolic activity are suitable for analyzing proliferation, 
viability and cytotoxicity. The reduction of tetrazolium salts MTT and WST to colored 
formazan compounds only occurs in metabolically active cells [303]. Actively proliferating 
cells increase their metabolic activity while cells exposed to toxins will have decreased 
activity [304]. Since overexpression of mPGES-1 and its product PGE2 are known to promote 
tumour growth acting via EP2 receptor and by that stimulate cell proliferation, apoptosis and 
angiogenesis it was interesting to elucidate whether miR-574-5p stimulates A549 cell 
proliferation. miR-574-5p promotes NSCLC migration and invasion in vitro but it did not 
affected A549 cell proliferation [275]. This stands in line with the results shown in Fig. 35. No 
significant cell proliferation changes were observed in unstimulated A549 in response to miR-
574-5p oe. Interestingly, an increase in IL-1β induced cell proliferation was observed in 
response to miR-574-5p oe, suggesting that inducing cytokine-dependent targets like 
mPGES-1 and miR-574-5p increase proliferation upon stimulation. CUGBP1 has been 
described to inhibit A549 cell proliferation [209]. In this study of Gao et al. a WST assay was 
used for the determination of the number of viable cells in cell proliferation. Contrary, trypan 
blue measurements revealed decreased cell viability in response to CUGBP1 oe in A549 
cells during time courses (Fig. 22). These data were confirmed by MTT assays which 
demonstrated a significant decrease in IL-1β induced proliferation in response to CUGBP1 
oe and a significant increase by depleting CUGBP1 (Fig. 25). It is known that the 
immunomodulatory cytokines, including IL-1β, TNF-α, and interferon-gamma (IFN) modulate 
the growth response in nonimmune cells and regulate cellular metabolism by inducing gene 
expression of biologically active molecules [305]. Interestingly, stable A549 miR-574-5p oe 
cells did not show increased cell proliferation (Fig. 37). The exact involvement of CUGBP1 
and miR-574-5p in cell migration and tumor invasion needs to be further investigated, since 
mPGES-1 may not be the only common target involved in cell proliferation. 
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5.5 miR-574-5p promotes lung tumor growth in vivo and may be a novel potent 
biomarker for NSCLC  
 
A function of miRNAs as oncogenes or tumour suppressors has been extensively described 
[249]. Compelling evidences have demonstrated that dysregulated miRNAs affect 
proliferation, apoptosis, tumour metastasis and angiogenesis. Although miRNAs have 
multiple targets, their function in tumourigenesis remains unclear and could be due to their 
regulation of few specific targets [306]. A growing number of miRNAs have been shown to 
target genes which play a key role in lung cancer progression [307,308]. miR-224 promotes 
tumor progression in NSCLC by shifting the equilibrium of the partially antagonist functions of 
SMAD4 and TNFAIP1 toward enhanced invasion and growth [309]. miR-221 and miR-222 
are involved in the development and progression of lung cancer by targeting PTEN and 
TIMP3 tumor suppressor genes [310,311]. Overexpressed miR-221/222 inhibits apoptosis 
and promotes cell migration by down-regulating PTEN and TIMP3. Recently, miR-574-5p 
has been described as one important serum-based biomarker for early-stage NSCLC [239]. 
The expression of miR-574-5p was significantly increased in serum samples obtained from 
patients with early-stage NSCLCs. Furthermore, it is known that tumour invasion and 
metastasis is regulated by miR-574-5p in lung cancer but the mechanisms behind these 
observations are unclear [274,275]. A549 cells which stable express miR-574-5p showed a 
strong increase in mPGES-1 expression and PGE2 formation. Since PGE2 is known to 
promote tumour growth by binding to EP2 receptor and stimulates thus cell proliferation, 
apoptosis and angiogenesis we were interested to see if miR-574-5p stimulates tumour 
growth via a PGE2-dependent mechanism. Additionally, it is known that PGE2 reduction by 
selective COX-2 inhibitors suppress the growth of established tumours including head and 
neck, colorectal, stomach, lung, breast, and prostate tumours [69,312]. Recently, two clinical 
studies showed an upregulation of miR-575-5p in blood and sera of lung tumours, 
demonstrating the important role as a potent biomarker for this cancer type. In the present 
study analysis of four NSCLC patients showed a significant upregulation of miR-574-5p in 
tumours compared to control, suggesting that miR-547-5p may play a critical role in tumour 
growth and development. This hypothesis was confirmed in a xenograft mouse model where 
injection of A549 cells overexpressing miR-574-5p into nude mice led to a highly significant 
induction of tumour growth and weight compared to A549 control cells which could be 
blocked with the selective mPGES-1 inhibitor CIII. The data suggest that miR-574-5p exhibits 
oncogenic properties and promotes tumour growth via the induction of mPGES-1-derived 
PGE2 synthesis. miR-574-5p may play a major role in the regulation of mPGES-1 dependent 
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PGE2 release in lung cancer and tumour growth. Therefore, miR-574-5p might offer a novel 
therapeutic target in treatment of lung cancer. 
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The terminal PGE synthase mPGES-1 converts PGH2 derived from the precursor 
arachidonic acid into the pro-tumourigenic PGE2 and is the key enzyme in the induced 
prostaglandin biosynthesis. mPGES-1-derived PGE2 causes inflammation including swelling, 
fever and inflammatory pain. Therefore, mPGES-1 is a potential target for the development 
of novel anti-inflammatory drugs that can reduce symptoms of inflammation hopefully without 
causing severe cardiovascular side effects as traditional NSARs or selective COX-2 
inhibitors may do. Here in this study, the regulation of mPGES-1 mRNA expression by post-
transcriptional mechanisms such as alternative splicing or mRNA stability was investigated. 
A novel mPGES-1 3´UTR variant was identified in the non-small lung cancer cell line A549 
and other cell types. This isoform is generated by splicing out a part of the 3´UTR. Here we 
could show that CUGBP1 binds to the GREs in the 3´UTR of mPGES-1. It was demonstrated 
that mPGES-1 3´UTR mRNA splicing and its subsequent degradation was mediated by 
CUGBP1 binding to GREs flanking both intron boundaries. This way of post-transcriptional 
regulation of mPGES-1 3´UTR by CUGBP1-dependent alternative splicing and rapid mRNA 
degradation is a powerful mechanism to reduce the amount of mRNA and protein. Additional, 
CUGBP1 repressed mPGES-1 translation obviously by recruiting mPGES-1 mRNA into P-
bodies. We have shown that CUGBP1 exerts several functions on mPGES-1 mRNA and 
protein. Furthermore, we unraveled an additional regulatory level on mPGES-1 expression 
by a miRNA. MiRNAs are small non-coding RNAs and bind to the 3´UTR of their target 
mRNA in a sequence-specific manner controlling the expression of target genes either by 
translational repression or mRNA degradation. Recently, a new regulatory mechanism has 
been discovered when it was found that miR-328 acts as a RNA decoy to modulate 
translational repressor activity of hnRNP E2 by direct binding. In this study, we identified a 
second miRNA which exerts such new regulatory mechanisms. miR-574-5p harbors a 
binding site for CUGBP1 and acts as RNA decoy to CUGBP1. CUGBP1 binds to mature 
miR-574-5p thereby preventing the mPGES-1 3´UTR isoform from GU-mediated mRNA 
decay and mPGES-1 protein from translation repression mediated by CUGBP1. We assume 
that miR-574-5p plays a key role in the regulation of PGE2 biosynthesis in inflammatory 
reactions by inhibiting CUGBP1 controlled mRNA decay and translation repression of 
mPGES-1. It is known that dysregulation of miRNAs contribute to the onset of cancer. Here it 
was shown that miR-574-5p is cytokine-dependent upregulated, suggesting its important role 
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in inflammation and micro environment of tumours. Indeed, in tumour tissue of NSCLC 
patients’ miR-574-5p was significantly upregulated. We could show that the balance of 
CUGBP1 and miR-574-5p regulates cell proliferation and mPGES-1-dependent PGE2 
synthesis. This hypothesis was confirmed in a xenograft mouse model where injection of 
A549 cells overexpressing miR-574-5p into nude mice led to a highly significant induction of 
tumour growth and weight compared to A549 control cells. This effect could be blocked with 
the selective mPGES-1 inhibitor CIII. Based on these results we proofed that miR-574-5p is 
an oncogene and may play a major role in the regulation of mPGES-1-dependent PGE2 
release in lung cancer and tumour growth. Therefore, miR-574-5p might offer a novel 
therapeutic target in treatment of lung cancer.  
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Die terminale PGE-Synthase mPGES-1 konvertiert PGH2, welches von der Arachidonsäure 
geliefert wird, in das tumorigene PGE2. In der induzierten Prostaglandin Biosynthese ist 
PGE2 eines der wichtigsten Enzyme. Es ist verantwortlich für Entzündungen, Schwellungen, 
Fieber und Schmerz. Für die Pharmaforschung stellt mPGES-1 ein potenzielles Zielmolekül 
dar, um neue anti-inflammatorische Medikamente zu entwickeln, welche die 
kardiovaskulären Nebenwirkungen von NSARs nicht mehr besitzen. In dieser Studie wurde 
die post-trankriptionelle Regulation der mPGES-1 untersucht. Hierbei wurde eine neue 
mPGES-1 3´UTR Variante in der NSCLC Zelllinie A549 und anderen Zelllinien gefunden, die 
durch alternatives Spleißen des 3´UTR generiert wurde. Hierbei wurde ein Teil des 3´UTRs 
durch Spleißen entfernt, was zum rapiden mRNA dieser 3´UTR Isoform führte. Es konnte 
gezeigt werden, dass sowohl für das Spleißen wie auch für den Abbau der mRNA CUGBP1 
verantwortlich ist. Diese Art der post-transkriptionellen Regulation des mPGES-1 3´UTR 
durch CUGBP1-abhängiges alternatives Spleißen und mRNA-Abbau ist ein wirksamer 
Mechanismus, um die Menge an mRNA und Protein zu reduzieren. Zusätzlich reprimiert 
CUGBP1 die Translation von mPGES-1, indem es  mPGES-1 mRNA in sogenannte P-
bodies rekrutiert. Somit konnte in dieser Arbeit gezeigt werden, dass CUGBP1 mehrere 
Funktionen auf die mRNA und das reife Protein von mPGES-1 ausübt und somit die 
Expression reprimiert. Darüber hinaus konnte wir einen weiteren Regulationsmechanismus 
für die mPGES-1 aufgedeckt werden. MiRNAs sind kleine nicht-kodierende RNAs, die 
sequenzspezifisch an den 3´UTR binden und durch Repression der Translation oder mRNA 
Abbau die Expression ihrer Zielgene kontrollieren. Kürzlich wurde jedoch ein neuer 
Interaktionsmechanismus von miRNAs endeckt. miR-328 agiert als „RNA Köder“ für hnRNP 
E2 und verhindert so die Bindung von hnRNP E2 and die mRNA und dadurch kommt es zur 
Translationsrepression. In dieser Studie identifizierten wir eine zweite miRNA, die einen 
solchen neuen regulatorischen Mechanismus ausübt. Die miR-574-5p besitzt eine 
Bindestelle für CUGBP1. CUGBP1 bindet an die reife miR-574-5p und verhindert dadurch 
den mRNA Abbau der 3´UTR Variante und die Repression der mPGES-1 Translation. Durch 
die Inhibierung der CUGBP1-vermittelten Reduktion der mPGES-1 Expression nimmt die 
miR-574-5p eine wichtige Rolle in der Regulation der PGE2 Biosynthese in entzündlichen 
Reaktionen ein. Oft wird die Dysregulation von miRNAs in Verbindung gebracht mit der 
Krebsentstehung und Krankheiten. Hier konnte gezeigt werden, dass miR-574-5p 
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zytokinabhängig hochreguliert wurde, was dafür spricht, dass diese miRNA eine wichtige 
Rolle in Mikromilieu von Tumoren und Entzündungen spielt. In der Tat war die Expression 
der miR-574-5p in Tumorgewebe von NSCLC Patienten signifikant hochreguliert. Zusätzlich 
konnten wir zeigen, dass die Balance von CUGBP1 und miR-574-5p die Zellproliferation und 
die mPGES-1 abhängige PGE2 Synthese reguliert, welche für die Tumorproliferation wichtig 
ist. Diese Hypothese wurde in einem Xenograft-Mausmodell bestätigt. Die Injektion von A549 
Zellen, mit stabiler miR-574-5p Überexpression, kam es zu einer signifikanten Induktion des 
Tumorwachstums verglichen mit der Kontrollgruppe. Dieser Effekt konnte mit dem selektiven 
mPGES-1-Inhibitor CIII blockiert werden. Die Ergebnisse haben gezeigt, dass miR-574-5p 
onkogene Eigenschaften besitzt, die das Tumorwachstum fördern. Die miR-574-5p spielt 
eine wichtige Rolle in der mPGES-1 abhängigen PGE2 Freisetzung in Lungenkrebs und 
Tumorwachstum und stellt deshalb ein potenzielles, therapeutisches Zielmolekül in der 
Behandlung von Lungenkrebs dar. 
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